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1.	Formal	statements	
1.1	Affidavit				
Eidesstattliche	Versicherung				Kunath,	Nicolas								Ich	erkläre	hiermit	an	Eides	statt,	dass	ich	die	vorliegende	Dissertation	mit	dem	Thema				
„Ghrelin	and	Cognition“					selbständig	verfasst,	mich	außer	der	angegebenen	keiner	weiteren	Hilfsmittel	bedient	und	alle	Erkenntnisse,	die	aus	dem	Schrifttum	ganz	oder	annähernd	übernommen	sind,	als	solche	kenntlich	gemacht	und	nach	ihrer	Herkunft	unter	Bezeichnung	der	Fundstelle	einzeln	nachgewiesen	habe.			Ich	erkläre	des	Weiteren,	dass	die	hier	vorgelegte	Dissertation	nicht	in	gleicher	oder	in	ähnlicher	Form	bei	einer	anderen	Stelle	zur	Erlangung	eines	akademischen	Grades	eingereicht	wurde.		 								Ort,	Datum										Unterschrift	des	Doktoranden			
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1.2	Abbreviations		AEBSF		 	 	 4-(2-Aminoethyl)benzensulfonylfluorid	ANOVA	 	 	 Analysis	of	Variance	AUC	 	 	 	 Area	under	the	curve	Aβ	 	 	 	 Amyloid	Beta	BET	 	 	 	 Brain	extraction	tool	 	 	 	BOLD	 	 	 	 Blood	oxygen	level	dependent	BOMAT	 	 	 Bochumer	Matritzentest	CNS	 	 	 	 Central	Nervous	System	COG	 	 	 	 Center	of	gravity	CREB	 	 	 	 cAMP	responsive	element-binding	(protein)	DAB	 	 	 	 3,3'-Diaminobenzidine	DCX	 	 	 	 Doublecortin	DPX	 	 	 	 Distrene,	Plasticiser,	Xylene	EGTA	 	 	 	 Ethylene	glycol-bis-N,N,N',N'-tetraacetic	acid	fMRI	 	 	 	 Functional	magnetic	resonance	imaging	G-Protein	 	 	 GTP	binding	protein	GH	 	 	 	 Growth	hormone	GHS-R		 	 	 Growth	hormone	secretagogue	receptor	GI	 	 	 	 Glycemic	index	GLM	 	 	 	 General	linear	model	IACUC		 	 	 Institutional	Animal	Care	and	Use	Committee	 	IBA	 	 	 	 Ibandronate	ICV	 	 	 	 Intracerebroventricular	JNK	 	 	 	 Janus	kinase	MCFLIRT	 	 	 Motion	correction	FMRIB's	Linear	Image	Registration	Tool	MWT-B	 	 	 Mehrfachwahl-Wortschatz-Intelligenztest	Version	B	NIH	 	 	 	 National	institute	of	health	NMDA		 	 	 N-Methyl-D-aspartate	(p-)IRS	 	 	 (phosphorylated)	insulin	receptor	substrate	PET	 	 	 	 Positron	emission	tomography	SAP	 	 	 	 Stress-activated	phospho(-kinase)	PSD	 	 	 	 Post-synaptic	density	PVT	 	 	 	 Psychomotor	vigilance	task	QMR	 	 	 	 Quantitative	magnetig	resonance	(imaging)	RDS	 	 	 	 Reverse	digit	span	RIPA	 	 	 	 Radioimmunoprecipitation	assay	ROI	 	 	 	 Region	of	interest	SD	 	 	 	 Standard	deviation	SEM	 	 	 	 Standard	error	of	the	mean	TE	 	 	 	 Echo	time	TgAPPSwDI	 	 	 Transgenic	amyloid	precursor	protein	Swedish-Dutch-Iowa	TNF	 	 	 	 Tumor	necrosis	factor	TR	 	 	 	 Relaxation	time	Tris	 	 	 	 Tris(hydroxymethyl)aminomethane	ZVT	 	 	 	 Zahlenverbindungstest			
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2.	Summary	
	
2.1	Zusammenfassung	(deutsch)	
	
2.1.1	Hintergrund		 Ghrelin	ist	ein	Peptid	mit	einer	Länge	von	28	Aminosäuren	und	besitzt	in	seiner	aktiven	Form	eine	charakteristische	Acyl-Seitenkette,	die	durch	das	Enzym	„Ghrelin-O-Acyltransferase“	am	dritten	Serin-Rest	angefügt	wird.	Es	wurde	1999	in	einer	japanischen	Arbeitsgruppe	als	Ligand	des	“Growth	Hormone	Secretagogue”-Rezeptors	entdeckt.	Der	Name	„Ghrelin“	ist	sowohl	Akronym	(growth	hormone	release	inducing)	als	auch	Anspielung	auf	die	proto-indo-europäische	Wortwurzel	“ghre”	für	“wachsen”.		Außer	seiner	Rolle	in	der	Freisetzung	von	Wachstumshormon	ist	Ghrelin	das	einzige	bislang	bekannte	periphere	orexigene	Peptidhormon	und	scheint	fester	Bestandteil	zirkadianer	Rhythmen	der	Nahrungsaufnahme	zu	sein.	Der	Rezeptor	findet	sich	an	vielen	Orten	in	Säugetierorganismen	und	besitzt	zudem	die	Eigenschaft,	Dimere	mit	Rezeptoren	anderer	Transmittersysteme	wie	z.B.	jenes	des	Serotonins	oder	des	Dopamins	zu	bilden.	Dies	zeigt	die	breite	Relevanz	Ghrelins	oder	vielmehr	des	„Ghrelin-Systems“,	das	mannigfach	auf	unseren	Energiehaushalt		aus	kognitiver	genauso	wie	metabolischer	Stoßrichtung	einzuwirken	scheint	–	sofern	diese	Trennung	überhaupt	aus	dem	Blickwinkel	der	Ghrelin-Forschung	vertretbar	ist:	Sehr	bald	legten	Forschungergebnisse	nahe,	dass	die	Bedeutung	dieses	Peptids	weit	über	die	reine	Regulation	des	Energiehaushalts	hinausgeht.		Es	scheint	vielmehr	auch	komplexe	kognitive	Prozesse	zu	beeinflussen.	An	Nagetiermodellen	konnte	konsistent	gezeigt	werden,	dass	Ghrelin	die	Gedächtnisbildung	unterstützt,	allen	voran	in	den	Bereichen	Objekterkennung,	räumliches	Lernen	und	aversives	Gedächtnis.	Es	wird	daher	als	eine	mögliche	Brücke	
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zwischen	Energiehaushalt	und	Kognition	diskutiert	und	erfüllt	daher,	bildlich	ausgedrückt,	in	mancher	Hinsicht	die	Rolle	eines	„Eichhörnchenhormons“:	Diese		Tiere	erinnern	sich	in	Zeiten	des	Fastens	mehr	oder	minder	präzise	an	die	Orte,	an	denen	Nahrung	zuvor	versteckt	wurde.	In	der	Tat	zeigten	jüngste	Projekte	an	Wildtieren	dieser	Gattung	eine	mögliche	Relevanz	Ghrelins	im	Stoffwechsel	dieser	Tiere	auf.	Im	angelsächsischen	Sprachgebrauch	ist	es	vor	allem	das	Bild	des	„belly-brain-links“,	das	den	gleichen	Sachverhalt	verdeutlichen	soll.	Nun	verbietet	sich	allerdings	die	direkte	Extrapolation	dieser	Daten	aus	Nagetiermodellen	und	Hörnchen	auf	den	Menschen	allein	schon	wegen	der	ungleich	komplexeren	Zusammenhänge	menschlicher	Kognition.	Dennoch	stellt	sich	die	Frage,	ob	Ghrelin	möglicherweise	einen	ebenso	positiven	Einfluss	auf	kognitive	Prozesse	des	Menschen	hat	–	ein	Sachverhalt	mit	möglicher	Relevanz	im	Verständnis	sowohl	der	Entwicklung	von	Übergewicht	als	auch	Anorexie.	Zwar	bestand	in	der	Arbeitsgruppe	Prof.	Axel	Steiger	(Principal	Investigator	der	Studie	2)	bereits	vor	Studie	2	eine	mehrjährige	Erfahrung	mit	der	Gabe	von	Ghrelin	bei		menschlichen	Probanden	unter	Fragestellungen	der	Schlafforschung	im	Allgemeinen	und	Schlafendokrinologie	im	Speziellen.	Eine	Untersuchung	der	Auswirkungen	Ghrelins	auf	die	menschliche	Gedächtnisleistung	war	jedoch	unseres	Wissens	nach	zuvor	noch	nie	erfolgt.		Damit	stellt	Studie	2	die	erste	Studie	ihrer	Art	dar,	die	die	menschliche	kognitive	Leistungsfähigkeit	unter	und	nach	Gabe	von	Acyl-Ghrelin	untersucht.	Aufgrund	seiner	neuroprotektiven	Wirkung	bei	neurodegenerativen	Erkrankungen	könnte	Ghrelin	in	Zukunft	eine	Rolle	als	Therapeutikum	bei	Alzheimer-Demenz	und	Parkinson	spielen.	Arbeiten	der	Forschungsgruppe	von	Dr.	Inga	Kadish	(Principal	Investigator	der	Studie	1)	zeigten	gar	eine	niedrigere	Belastung	mit	A-Beta-Plaques	im	Alzheimer-Mausmodell	unter	chronischer	Behandlung	mit	einem	Ghrelinagonisten	bei	gleichzeitig	besserer	kognitiver	Leistung	der	Nagetiere	im	
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Vergleich	zur	Placebo-Kontrollgruppe.	Nicht	abschließend	geklärt	ist	nach	wie	vor,	über	welchen	Mechanismus	Ghrelin	diese	protektive	Wirkung	entfaltet,	einige	mögliche	Hypothesen	z.B.	über	eine	Beeinflussung	der	Signalwege	des	Insulin-Systems,	werden	in	Studie	1	verfolgt	und	diskutiert.		Gleichzeitig	hat	Ghrelin	insulinostatische	Eigenschaften	und	ist	daher	möglicherweise	ein	relevanter	Faktor	in	der	Pathogenese	von	Diabetes	mellitus.	Sehr	oft	postuliert	wurde	ein	diabetogener	Effekt	Ghrelins	durch	die	Begünstigung	hoher	Serum-Glukosewerte	mittels	Unterdrückung	der	Sekretion	von	Insulin.	An	dieser	Stelle	ergibt	sich	ein	Widerspruch	zu	der	mittlerweile	nachgewiesenen	und	weithin	akzeptierten	pathoätiologischen	Verbindung	von	Diabetes	und	Neurodegeneration:	Ist	Ghrelin	nun	wie	bereits	erwähnt	aufgrund	seiner	neuroprotektiven	Wirkung	ein	potentielles	Therapeutikum	für	neurodegenerative	Erkrankungen?	Oder	begünstigt	die	chronische	Ghrelingabe	schlussendlich	die	Entwicklung	einer	diabetogenen	Stoffwechsellage	und	führt	im	Gegenteil	nicht	nur	zu	einem	erheblich	erhöhten	Diabetesrisiko	sondern	auch	langfristig	zu	einer	Schädigung	des	Nervensystems?	An	dieser	Stelle	setzt	Studie	1	an,	indem	sie	eine	chronische	Gabe	eines	Ghrelinagonisten	nicht	nur	im	Hinblick	auf	kognitive	sondern	auch	metabolische	Effekte	untersucht.	
	
2.1.2	Studie	1		 Aus	entwicklungsgeschichtlicher	Perspektive	dauerten	bzw.	dauern	Fastenperioden	selten	nur	einige	Stunden.	Krankheiten	wie	Alzheimer-Demenz	und	Diabetes	sind	chronische	Erkrankungen,	die	sich	über	Jahre	und	Jahrzehnte	entwickeln.	Nichtsdestotrotz	schlossen	frühere	Ghrelin-Studien	selten	Zeiträume	von	mehr	als	zwei	Wochen	in	ihre	Beobachtungen	ein.	Daher	war	es	Anliegen	von	Studie	1,	die	langfristigen	Effekte	eines	Ghrelinagonisten	auf	gleichermaßen	Kognition	und	
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Stoffwechsel	zu	beleuchten	(s.o.).	Dazu	wurde	ein	APPSwDI-Mausmodell	mit	einem	Ghrelinagonisten	(LY444771)	mehr	als	vier	Monate	lang	behandelt.	Gleichzeitig	wurde	ein	Teil	der	Versuchstiere	mit	eigens	entwickeltem	Futter	mit	einem	hohen	glykämischen	Index	gefüttert.	Während	die	Studie	die	positive	Wirkung	des	Agonisten	auf	kognitive	Endpunkte	bestätigen	konnte,	zeigte	sich	überraschender	Weise	keinerlei	Einfluss	des	Agonisten	auf	die	Glukosetoleranz.	Kaum	ein	Unterschied	bestand	zwischen	den	unterschiedlichen	Futtersorten,	auch	die	Kombination	aus	Ghrelin	und	hohem	glykämischem	Index	führte	zu	keinerlei	Verschlechterung	der	Glukosetoleranz.		Zudem	kam	die	Studie	überraschender	Weise	zu	dem	Schluss,	dass	eine	chronische	Gabe	des	Ghrelinagonisten	nicht	zu	einer	chronisch	erhöhten	Nahrungsaufnahme	und	damit	zu	chronischer	Gewichtszunahme	bei	der	Versuchstieren	führte,	ohne	jedoch	eine	überzeugende	Erklärung	für	diese	Beobachtung	vorweisen	zu	können.	
2.1.3	Studie	2		Die	zweite	Studie	war	die	erste,	die	systematisch	den	Einfluss	von	Ghrelin	auf	menschliche	Kognition	untersuchte.	Aufgrund	der	vielversprechenden	Ergebnisse	aus	Nagetiermodellen	lautete	die	Arbeitshypothese	dieser	Studie,	dass	die	Einmalgabe	von	Acyl-Ghrelin	die	Gedächtnisleistung	gesunder	Menschen	möglicherweise	verbessert.	Die	Ergebnisse	konnten	dies	jedoch	nicht	bestätigen.	21	gesunde	männliche	Probanden	mussten	in	einem	Paradigma	zum	räumlichen	Lernen	geschriebene	Begriffe	in	einer	dreidimensionalen	virtuellen	Umgebung	mit	ihrer	Lokalisation	erlernen.		Ghrelin	veränderte	zwar	die	Hirnaktivität	(BOLD	fMRI)	in	Hirnregionen,	die	bekannter	Weise	eine	Rolle	in	der	Verarbeitung	von	wortbezogenen	Assoziationen	spielen	und	beeinflusste	auch	die	Konnektivität	in	neuronalen	Netzwerken	z.B.	zwischen	dem	beidseitigen	Nucleus	caudatus,	dem	rechten	orbitofrontalen	Kortex	und	der	
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beidseitigen	Inselrinde.	Überraschenderweise	fand	sich	jedoch	kein	Effekt	des	Hormons	in	den	getesteten	kognitiven	Disziplinen:	Arbeitsgedächtnis,	Bochumer	Matrizentest,	Kreativität,	Zahlenverbindungstest,	Reaktionsgeschwindigkeit	und	Aufmerksamkeit.	Eine	weitere	Teilhypothese	lautete,	dass	Ghrelin	möglicherweise	dazu	führt,	dass	sich	Probanden	nahrungsbezogene	Begriffe	besser	einprägen	und	dies	umso	mehr,	je	attraktiver	oder	kalorienreicher	die	Nahrung	ist.	Ein	solcher	Zusammenhang	konnte	ebenfalls	nicht	nachgewiesen	werden.		Letztlich	scheint	der	Einfluss	von		Ghrelin	auf	menschliche	Kognition	komplexer	zu	sein	als	erwartet,	doch	sind	auch	die	Einschränkungen	der	Studie	zu	erwägen:	Statt	geschriebener	Begriffe	sollten	künftige	Studien	Bilder	von	Gegenständen	und	Nahrungsmitteln	verwenden,	die	erfahrungsgemäß	in	neurokognitiven	Experimenten	eine	höhere	Salienz	besitzen.	Zudem	verbessert	Ghrelin	sehr	wahrscheinlich	nach	Einmalgabe	auch	nicht	die	Denkleistung	gesunder	Versuchspersonen.	Doch	stellt	die	Untersuchung	von	längeren	Fastenperioden	oder	chronischen	Ghrelingaben	beim	Menschen	einen	interessanten	Ansatz	dar,	die	Auswirkungen	des	Hormons	auf	kognitive	Prozesse	am	Menschen	weiter	zu	beleuchten.	
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2.2	Summary	(English)	
	
2.2.1	Background		Ghrelin	is	a	28-aminoacid	peptide	with	a	distinct	acyl-chain	at	its	third	serine	residue,	added	by	the	enzyme	ghrelin-O-acyl-transferase.	It	was	discovered	in	1999	as	a	ligand	of	the	growth	hormone	secretagogue	receptor	by	a	Japanese	research	group.	Its	name	is	both	an	acronym	(growth	hormone	release	inducing)	and	an	allusion	to	the	Proto-Indo-European	word	fragment	“ghre”,	meaning	“to	grow”.		Besides	its	role	in	growth	hormone	release,	it	has	been	identified	as	the	only	peripheral	orexigenic	hormone	and	appears	to	be	an	integral	part	of	circadian	rhythms	of	food	intake.	The	receptor	is	widely	spread	in	mammal	organisms	and	further	has	the	capacity	of	forming	heterodimers	with	other	transmitter	systems	such	as	the	serotonin	or	dopamine	system.	This	shows	the	broad	relevance	of	ghrelin	or	rather	the	“ghrelin	system”	interacting	in	a	myriad	of	ways	with	aspects	of	energy	homeostasis	both	from	a	metabolic	and	a	cognitive	perspective	–	if	this	separation	can	be	validly	upheld	in	ghrelin	research.		Soon	it	became	clear	that	its	importance	and	impact	goes	far	beyond	the	regulation	of	energy	homeostasis.	It	rather	seems	to	influence	and	shape	cognitive	processes,	consistently	improving	memory	formation	in	different	rodent	models,	mainly	in	the	fields	of	object	recognition,	spatial	learning	and	aversive	memory.	It	is	being	discussed	as	a	link	between	metabolism	and	cognition	and	therefore	has	in	many	ways,	metaphorically	speaking,	the	role	of	a	“belly-brain	link”	or	“squirrel	hormone”:	In	times	of	fasting,	these	animals	remember	more	or	less	accurately	where	their	food	is	hidden.	Indeed	recent	projects	show	a	relevance	of	ghrelin	in	metabolic	aspects	in	sciurid	hibernators.	However,	a	direct	extrapolation	of	data	from	rodent	models	or	sciurid	
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hibernators	to	humans	cannot	be	validly	done	due	to	the	much	more	complex	context	of	human	cognition.	Nonetheless,	it	is	an	interesting	and	very	relevant	question	whether	ghrelin	has	a	positive	impact	on	human	cognitive	performance	as	well	since	it	may	help	explain	the	cognitive	aspects	of	feeding	in	humans	with	implications	in	understanding	both	obesity	and	anorexia.		There	has	been	a	longstanding	experience	in	experiments	involving	the	administration	of	ghrelin	to	human	volunteers	even	before	study	2	in	Prof.	Axel	Steiger’s	(principal	investigator	study	2)	research	group	in	the	context	of	sleep	research	in	general	and	more	specifically	sleep	endocrinology.	However,	to	our	knowledge,	no	study	had	systematically	looked	at	the	impacts	of	ghrelin	on	human	cognitive	performance.	Thus,	study	2	is	the	first	of	its	kind	looking	into	the	cognitive	aspects	of	ghrelin	action	in	humans	during	and	after	the	administration	of	acyl	ghrelin.	Due	to	its	beneficial	impact	in	neurodegenerative	diseases	ghrelin	might	play	a	role	as	a	therapeutic	agent	in	conditions	such	as	Alzheimer’s	and	Parkinson’s	disease.	Projects	of	Dr.	Inga	Kadish’s	(principal	investigator	study	1)	research	group	even	showed	a	lower	A-beta-plaque	load	and	better	cognitive	performance	after	chronic	treatment	with	a	ghrelin	agonist	in	an	Alzheimer’s	disease	mouse	model	compared	to	controls	treated	with	placebo.	A	conclusive	mechanism	for	this	protective	effect	has	not	been	identified	yet,	some	possible	hypotheses	e.g.	via	influencing	signaling	pathways	of	the	insulin	system	are	presented	and	discussed	in	study	1.		At	the	same	time,	ghrelin	has	insulinostatic	properties,	making	it	a	relevant	hormonal	player	in	diabetes,	possibly	helping	to	explain	the	link	between	both	conditions.	It	has	often	been	postulated	that	ghrelin	might	be	a	diabetogenic	factor	as	it	raises	serum	glucose	levels	via	a	reduction	of	insulin	release.	This	idea	stands	in	harsh	contrast	to	the	well-proven	and	widely	accepted	connection	of	diabetes	and	
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neurodegeneration:	Is	ghrelin	as	mentioned	before	a	possible	therapeutic	agent	in	neurodegenerative	diseases	due	to	its	neuroprotective	effect	shown	in	numerous	studies?	Or	does	ghrelin	after	all	favor	a	diabetogenic	metabolic	situation	leading	to	a	higher	risk	of	developing	diabetes	and	thus	to	a	long-term	threat	to	the	integrity	of	the	nervous	system?	This	is	the	idea	of	study	1	looking	into	the	chronic	administration	of	a	ghrelin	agonist	not	only	with	respect	to	cognitive	but	also	to	metabolic	effects.	
	
2.2.2	Study	1		 Seen	from	an	evolutionary	perspective,	periods	of	fasting	were	and	are	rarely	short-term	events	of	a	few	hours	and	diseases	such	as	Alzheimer’s	and	diabetes	are	intrinsically	chronic	diseases	with	a	pathoetiological	onset	of	potentially	years	and	decades.	Nonetheless,	early	studies	looking	into	ghrelin’s	effects	in	these	conditions	hardly	ever	covered	periods	of	more	than	a	couple	of	weeks.	Thus,	the	first	study	aimed	at	creating	a	paradigm	looking	into	the	long-term	effects	of	a	ghrelin	agonist	on	both	cognitive	and	metabolic	endpoints	by	treating	an	APPSwDI	mouse	model	with	a	ghrelin	agonist	(LY444771)	for	more	than	four	months.		At	the	same	time,	some	animals	were	fed	with	a	specifically	developed	high	glycemic	index	diet.	While	ghrelin’s	positive	influence	on	cognition	in	this	mouse	model	could	be	confirmed	in	this	study,	it	surprisingly	showed	no	negative	impact	of	the	agonist	on	glucose	tolerance	when	given	in	a	long-term	regimen.	There	was	hardly	any	difference	between	the	different	diets,	even	the	combination	of	ghrelin	and	a	high	glycemic	index	diet	did	not	lead	to	a	significant	deterioration	of	glucose	tolerance.	Surprisingly,	one	of	the	study’s	conclusions	was	that	chronic	treatment	with	a	ghrelin	agonist	did	not	lead	to	a	chronically	elevated	food	intake	and	consequently	to	a	chronic	weight	gain,	however,	without	finding	a	convincing	reason	for	this	observation.	
	 17	
2.2.3	Study	2		 The	second	study	was	the	first	one	to	systematically	look	at	the	hormone’s	effects	on	human	cognition.	With	the	promising	results	from	rodent	models	in	mind,	the	study’s	hypothesis	was	that	a	single	administration	of	acyl	ghrelin	could	improve	memory	formation	in	healthy	volunteers.	Results	however	did	not	show	any	improvement	of	memory	in	a	spatial	learning	paradigm	in	which	21	healthy	male	volunteers	had	to	memorize	written	words	with	their	location	in	a	three-dimensional	virtual	environment.	Ghrelin	altered	brain	activity	as	measured	by	BOLD	fMRI	in	brain	areas	known	to	be	involved	in	verbal	association	processing	and	also	influenced	connectivity	between	several	brain	regions	such	as	the	bilateral	caudate	nucleus	and	the	right	orbitofrontal	cortex	and	the	bilateral	insula.	Surprisingly,	it	did	not	affect	any	of	the	cognitive	disciplines	tested	in	this	study:	working	memory,	fluid	reasoning,	creativity,	mental	speed,	reaction	time	and	attention.		Another	hypothesis	postulated	a	differential	effect	of	ghrelin	on	the	memorization	of	food	and	nonfood	items	with	a	better	effect	for	food	items,	also	dependent	on	their	attractiveness	and	caloric	value.	However,	we	did	not	see	any	significant	difference	between	food	and	nonfood	items	dependent	on	ghrelin	administration,	nor	was	there	a	difference	between	food	items	regarding	their	caloric	value.	After	all,	ghrelin’s	impacts	on	human	cognition	appear	to	be	more	complex	than	anticipated.	However,	we	do	see	the	limitations	of	our	study:	Future	projects	should	use	pictures	instead	of	written	words	as	they	usually	have	a	higher	salience	in	neurocognitive	experiments.		Looking	at	the	results	of	this	study,	a	single	administration	of	ghrelin	most	likely	does	not	act	as	a	cognitive	enhancer	in	healthy	subjects.	However,	it	certainly	is	a	promising	approach	for	future	studies	to	look	at	prolonged	periods	of	fasting,	or	even	a	
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chronic	administration	of	ghrelin	in	human	volunteers	in	order	to	further	characterize	the	hormone’s	properties	as	a	neuropeptide	in	humans.	
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3.	Introduction	
	
3.1	Food	for	thought:	Cognitive	aspects	of	feeding		Regarding	the	pivotal	role	of	food	intake	in	the	quest	to	survive	and	to	progenerate,	it	appears	evident	why	virtually	all	aspects	of	feeding	behaviour	are	intrinsically	finely	regulated	cognitive	processes.	The	act	of	looking	for	food,	the	choice	of	what	to	eat,	when	and	where	as	well	as	the	questions	of	how	to	prepare	for	periods	of	absence	of	food,	of	how	to	cooperate	for	the	common	goal	of	feeding	or	of	how	to	defend	one’s	food	once	it	is	obtained	are	probably	not	only	aspects	of	cognition	but	possibly,	at	least	in	part,	at	the	origin	of	what	we	define	today	as	the	abstract	concept	of	cognition.	Or	plainly,	as	we	put	it	in	a	previously	published	book	chapter1	on	ghrelin’s	role	in	memory	related	processes:	As	the	act	of	eating	in	evolution	has	only	recently	become	as	easy	as	to	open	a	fridge	filled	with	delicious	treats,	there	is	a	fundamental	need	for	all	living	organisms	to	establish	a	close	link	between	energy	needs	and	thinking,	between	craving	for	food	and	behaviour,	between	belly	and	brain.		
3.2	Thought	for	food:	the	complexity	of	energy	homeostasis		However,	when	it	comes	to	defining	the	different	elements	of	this	link	that	is	rather	a	delicate	network	of	neuroendocrine	processes,	the	role	of	each	piece	in	the	mosaique	is	usually	complex	and	rarely	unequivocally	clear,	thinking	of	the	many	impacts	on	cognition	of	factors	such	as	leptin,	insulin,	glucagone	and	cortisol	just	to	name	a	few.		In	the	quest	to	define	the	role	of	each	element,	researchers	are	facing	the	difficulty	to	standardize	their	studies	for	all	other	factors,	although	they	may	still	be	unknown	to	a	certain	extent.	At	the	same	time,	to	make	sense	of	the	results,	the	puzzle	as	a	whole	has	
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to	be	taken	into	consideration.	Even	more	so	in	the	case	of	ghrelin	whose	interaction	with	and	embedding	in	the	signalling	systems	of	other	peptides	involved	in	the	regulation	of	energy	homeostasis	(see	below)	is	only	starting	to	emerge.				
Table	A:	Ghrelin	at	a	glance						
Discovery	 1999	(Kojima	et	al.2)	
	
Characteristics	
	28	aminoacids,	acylation	(n-octanoylation)	at	Serin3-residue	characteristic	for	active	form	
	
Characterization	as	an	
orexigen	
	2000	(Tschöp	et	al.3)	
	
Characterization	as	a	
neuropeptide	relevant	
in	behaviour/cognition	
	From	2002	onwards	(most	notably	Carlini	et	al.,	Diano	et	al.4–7)	
	
Relevance	in	sleep	
	From	2003	onwards	(Weikel,	Rosenhagen,	Steiger	et	al.8)	
	
Main	place	of	
production	in	mammals	
	Oxyntic	cells	of	the	stomach;	receptor	apparently	ubiquitous	in	mammal	organism	
	
Receptor	
	Growth-hormone	secretagogue	receptor	(GHS-R)	
	
Agonists	for	use	in	
humans	(clinically	
approved/in	phase	III)	
	Pralmorelin	(approved,	Kaken	Pharma,	Sella	Pharma;	GH	deficiency	diagnostic),	Macimorelin	(phase	III,	Aeterna	Zentaris;	GH	deficiency	diagnostic),	Anamorelin	(phase	III,	Helsinn,	cancer	cachexia/anorexia,	for	a	comprehensive	list	see	review	“Ghrelin”	by	Müller	et	al.9)		
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3.3	The	story	of	ghrelin:	a	hunger	hormone	with	a	taste	for	memory	
enhancement?		Shortly	after	its	discovery	as	a	growth	hormone	secretagogue	produced	predominantly	in	the	stomach2,	first	studies	in	rodents	attributed	an	orexigenic	role	to	the	peptide,	increasing	food	intake	and	weight	gain	when	given	regularly	over	a	period	of	a	few	days3.	Soon	after,	rodent	experiments	could	show	an	effect	on	behaviour,	mainly	on	aversive	memory	as	demonstrated	by	Carlini	et	al.4	This	group	administered	ghrelin	ICV	in	a	rat	model,	the	main	behavioural	read-out	was	a	step-down	inhibitory	avoidance	task.	Carlini	and	colleagues	could	also	demonstrate	a	positive	influence	of	ghrelin	on	object	recognition	in	a	mouse	model10.	Ghrelin’s	enhancing	effects	on	aversive	memory	and	object	recognition	were	confirmed	by	other	groups:	Goshadrou	et	al.	observed	that	ghrelin	can	prevent	the	negative	impacts	of	an	NMDA-receptor	antagonist	on	cognition	in	a	passive	avoidance	task11.	Atcha	et	al.	showed	better	performance	in	object	recognition	for	a	ghrelin	agonist12.		However,	looking	at	ghrelin’s	behavioural	effects,	some	questions	and	inconsistencies	remain:	Carlini’s	study	on	object	recognition	used	a	food-restricted	mouse	model	in	which	negative	impacts	of	food	restriction	on	memory	performance	were	counteracted	by	ghrelin.	Further,	one	landmark	study	by	Diano	et	al.	observed	impairments	in	spatial	memory	but	not	in	aversive	memory	in	ghrelin	receptor	knock-out	mice7.	While	different	ways	of	ghrelin	administration	–	oral12,	subcutaneous7,	ICV4	–	all	seem	to	be	effective,	only	memory	acquisition	and	not	retrieval	appears	to	be	positively	influenced	by	ghrelin	at	least	in	a	rodent	model6.	On	top	of	that,	one	study	observed	better	memory	performance	in	GHS-R1a	knock-out	mice13,	others	reported	impaired	memory	performance	in	neonatal	chicks5	after	central	ghrelin	and	in	correlation	with	endogenous	ghrelin	in	humans14.	Many	of	these	points	may	be	
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explained	with	regard	to	the	caveats	of	each	individual	study	design	and	model	organism	used.	However,	they	clearly	show	that	ghrelin’s	unquestionable	influence	on	cognition	in	general	might	reach	beyond	the	complexity	of	a	mere	cognitive	enhancer	and	that	all	extrapolation	between	species	has	to	be	done	with	utmost	care.	However,	with	further	studies	also	reporting	a	positive	effect	on	spatial	memory	and	even	spine	synapse	density	and	long-term	potentiation7,15,	a	possible	role	of	ghrelin	as	a	neurocognitive	enhancer	was	increasingly	discussed,	further	supported	by	the	henceforth	emerging	role	of	ghrelin	in	neurodegenerative	diseases16–18	such	as	Alzheimer’s	and	Parkinson’s	disease.	Looking	beneath	these	behavioural	results,	the	transmitter	systems	and	biochemical	signaling	pathways	involved	in	the	mediation	of	ghrelin’s	actions	form	a	rather	complex	picture.	First,	ghrelin	has	an	impact	on	different	transmitter	systems	such	as	serotonin19,	nitric	oxide15,	glutamate20	and	dopamine21.	Second,	ghrelin	appears	to	act	via	a	G-protein	coupled	intracellular	signaling	pathway22,	leading	to	changes	in	intracellular	calcium	availability	via	the	second	messenger	insositol	trisphosphate23,	which	is	a	rather	common	biochemical	cascade.	Further,	CREB	seems	to	be	influenced	by	ghrelin	signaling24.	Currently,	these	pieces	of	information	(discussed	in	detail	in	a	previously	published	book	chapter1)	form	a	piecemeal	mosaic	that	still	needs	more	studies	in	order	for	us	to	deduce	a	real	mechanistic	relevance	and	understanding	from	it.	Key	to	understanding	the	extremely	widespread	actions	of	the	ghrelin	system	may	be	the	capacity	of	the	GHS-R	to	form	heterodimers	with	other	receptor	systems25,26.		Two	of	the	main	neurophysiological	correlates	of	ghrelin’s	impact	on	memory	formation	are	increased	hippocampal	long	term	potentiation	and	spine	synapse	density,	both	identified	by	Diano	and	colleagues7.	More	recent	studies	further	consolidate	the	
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notion	of	ghrelin	as	a	neuropeptide	relevant	in	hippocampal	memory	formation	by	showing	that	ghrelin’s	orexigenic	actions	are	to	a	certain	degree	mediated	via	neural	pathways	involving	hippocampal	subfields27,28.	As	mentioned	before,	ghrelin	influences	a	number	of	different	neuroendocrine	systems.	It	also	appears	to	play	a	role	in	the	regulation	of	the	hypothalamic-pituitary-adrenal	axis29,	thus	becoming	relevant	in	sleep	and	mental	health8,30–36.	The	two	studies	of	this	dissertation	were	not	designed	to	address	these	issues	and	rather	focused	on	endpoints	relating	to	memory,	cognition	as	well	as	energy	homeostasis.			
3.4	Does	ghrelin	act	as	a	cognitive	enhancer	in	young,	healthy,	male	humans?			A	peptide	enhancing	memory	in	feeding-related	processes	in	a	state	of	hunger	could	be	seen	as	an	evolutionary	advantage.	In	our	book	chapter,	we	used	a	squirrel	that	has	to	remember	in	winter	where	its	acorns	are	hidden	as	an	illustrating	example1.	Although	current	studies	indeed	confirm	ghrelin’s	relevance	in	the	metabolism	of	sciurid	hibernators	caught	in	the	wilderness	of	Colorado37,38,	its	relevance	for	memory	processes	in	this	species	has	yet	to	be	assessed.	Nontheless,	we	pursued	the	to	a	certain	extent	counterintuitive	idea	of	an	orexigen	improving	cognitive	performance	and	included	the	hormone	in	the	multicentre	research	project	“Comparing	Apples	with	Oranges:	A	Differential	View	on	Neuroenhancement”	supported	by	Volkswagen	Stiftung39	looking	into	the	cognitive	effects	of	a	number	of	substances.	Furthermore,	few	studies	had	and	have	addressed	the	effects	of	ghrelin	on	human	memory	performance	so	far.	Although	a	number	of	clinically	tested	ghrelin	agonists	is	available9	(see	table	A),	we	decided	to	design	a	study	employing	the	natural,	active	(acylated)	form	of	the	hormone	to	stay	as	close	to	natural	conditions	as	possible.	The	problems	arising	from	this	
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decision	such	as	the	time-sensitive	administration40	and	the	handling	of	the	fragile	peptide	are	pointed	out	in	the	methods	part	of	the	second	publication.				
	
Figure	A:	(left)	Golden	mantled	ground	squirrel	(Spermophilus	lateralis,	photo:	Eborutta	2003/Creative	
Commons	license)	–	metabolism	of	this	sciurid	hibernator	indeed	appears	to	be	affected	by	ghrelin;	(right)	
key	topics	in	ghrelin	research	and	recommended	reading			 It	is	important	to	note	that	this	study	dubbed	“GHREEN”	(ghrelin	and	cognitive	
enhancement)	did	not	seek	to	define	the	effects	of	hunger	on	cognition	as	this	would	be	far	beyond	the	scope	of	a	single	study.	It	rather	aimed	at	characterizing	the	acute	effects	of	acyl	ghrelin	on	certain	aspects	of	human	cognition	(see	“methods”	study	2)	directly	in	the	aftermath	of	administration.			
3.5	The	methodological	challenge	of	designing	a	suitable	paradigm	for	the	
question		As	measuring	the	amount	of	acyl	ghrelin	actually	reaching	the	CNS	would	hardly	be	ethically	justified	in	a	sample	of	healthy	volunteers,	we	decided	to	monitor	peripheral	bioavailability	instead.	We	were	aware	of	consequently	leaving	the	question	of	
Topic	 	 	 	 Publication/Review	article		Overview:	Ghrelin	 	 Müller	et	al.	2015	Ghrelin	&	Memory	 	 Kunath/Dresler	2014	Ghrelin	&	Insulin	 Chabot	et	al.	2014,	Tong	et	al.	2010,	Dezaki	2013	Ghrelin	&	Sleep	 	 Steiger	et	al.	2011	Ghrelin	&	Mental	Health	 	 Wittekind/Kluge	2015	Ghrelin	&	Neurodegeneration	 Gahete	et	al.	2011,	Bayliss	et	al.	2013,	Shi	et	al.	2016	Ghrelin	as	a	belly-brain	link	 Hsu	et	al.	2016		
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interindividual	differences	in	ghrelin’s	central	bioavailability	to	future	studies	and	to	accept	the	uncertainty	of	differences	in	this	respect	within	our	sample	of	volunteers	–	despite	the	great	efforts	to	standardize	as	much	as	possible	for	environmental	and	biometric	variability.	A	number	of	studies	have	addressed	the	questions	of	how	ghrelin	crosses	the	blood-brain	barrier41,	what	factors	influence	the	existing	transport	mechanisms42	and	what	central	networks	mediate	the	subsequent	response	to	ghrelin	signalling27.	In	future	studies,	it	will	be	crucial	to	define	the	exact	relevance	of	each	of	these	pathways	–	active	bidirectional	transport,	vagal	afferences,	passive	diffusion	e.g.	via	circumventricular	organs	–	not	only	with	respect	to	ghrelin’s	orexigenic	actions	but	also	to	other	aspects	of	cognition	as	far	as	they	can	be	separated	from	each	other.	Further	adding	to	the	complexity	of	characterizing	ghrelin	signalling,	recent	studies	show	that	ghrelin	release	and	action	appear	to	be	regulated	in	a	circadian	manner	and	influenced	by	the	current	metabolic	state	of	the	individual	as	well	as	food	anticipation28,43–45.	In	designing	the	in-fMRI	memory	task,	we	tried	to	create	a	paradigm	for	visuo-spatial	memory	in	humans,	capable	of	making	a	difference	between	food-	and	non-food	items	realistically	embedded	in	a	virtual	surrounding	imitating	a	walk	in	an	everyday	environment.	While	at	the	beginning,	a	considerable	effort	was	made	to	use	a	real	walk	in	a	local	park	as	a	setting	for	the	task,	we	later	decided	to	abandon	this	idea	for	the	sake	of	better	standardization	possibilities	in	a	virtual	surrounding	and	created	a	custom-built	virtual,	three-dimensional	memory	task	based	on	the	freeware	virtual	gaming	software	“Sauerbraten”	(see	“Methods”	publication	2).	However,	with	the	recall	task	after	one	day	showing	merely	screenshots	of	the	virtual	environment	and	with	our	volunteers	often	reporting	a	memorizing	strategy	employing	certain	landmarks	such	as	houses,	rooms	or	streets	associated	with	the	items	
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to	be	recalled,	our	task	rather	turned	out	to	be	a	cued	word-location	association	task.	Furthermore,	it	needs	to	be	pointed	out	that,	for	a	better	graphical	embedding	of	items	into	the	virtual	task,	we	used	written	words	instead	of	pictures,	which	rises	the	very	valid	question	of	how	salient	the	items	we	used	actually	were.	Nonetheless,	within	the	limits	described	above,	we	are	certain	that	our	conclusion	that	ghrelin	does	not	globally	enhance	cognitive	performance	in	young,	male	humans	is	valid,	especially	with	Bayesian	analyses	being	in	favour	of	the	null	model	(see	publication	2).	First	of	all,	our	paradigm	tested	a	large	number	of	cognitive	disciplines.	Secondly,	differences	between	treatment	groups	were,	in	most	cases,	virtually	non-existent	and	did	not	even	come	close	to	a	statistical	trend	or	significance.	Thirdly,	volunteers	showed	an	extraordinarily	high	adherence	to	the	study	design,	with	an	overall	high	motivation	to	perform	well	in	the	cognitive	tasks	and	a	low	drop-out	rate	once	the	study	was	entered.	However,	with	another	group’s	work	pointing	in	this	direction46	and	with	our	study’s	limitations	in	mind,	we	do	think	that	there	is	a	possibility	of	finding	a	difference	for	memory	performance	in	food-	and	non-food	items	once	a	study	design	involving	e.g.	more	salient	stimuli	is	employed.									
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			 Study	1	 Study	2	
Drug	used	 Ghrelin	agonist	LY444711	 Natural	active	peptide	
Timeframe	 Long-term	(months)	 Acute	(intra-day)	
Organism	 Mouse	model	(C57/BL6	APPSwDI)	 Young,	healthy,	male	humans	(20-30	years	of	age)	
Main	question	 Long-term	effect	of	a	ghrelin	agonist	on	Alzheimer’s	disease	pathology	and	glucose	homeostasis	under	the	influence	of	a	high-glycemic-index	diet	
Effects	of	acute	administration	of	acyl	ghrelin	on	human	different	disciplines	of	human	cognition	
Main	paradigms	 Water	maze	test,	oral	glucose	tolerance	test,	immunohistochemical	stainings	of	brain	slices	
Custom-built	fMRI-monitored	virtual	cued	location-word	association	task;	cognitive	test	battery	(see	methods	study	2)	
Ghrelin	monitoring	 Once	at	the	end	of	the	study	 Constantly	(hourly	to	every	10-15min)	
Ghrelin	assay	used	 2-site	sandwich	assay47	 Radioimmunoassay	
N=	 36	 21	
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Volkswagen-Stiftung,	“Comparing	Apples	with	Oranges:	A	Differential	View	on	Neuroen-hancement”,	2011	
	
Table	B:	The	two	publications	at	a	glance		
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3.6	Neurodegeneration	and	the	role	of	insulin,	glucose	–	and	ghrelin?			Ever	since	the	Rotterdam	study	provided	convincing	evidence	of	a	direct	association	between	Alzheimer’s	disease	and	diabetes48	(a	link	between	cognitive	decline	and	diabetes	had	been	suggested	long	before),	science	tries	to	find	a	mechanistic	explanation	for	this	correlation.	Early	studies	had	long	contradicted	the	assumption	of	the	brain	being	an	organ	insensitive	to	insulin	signalling49,50.	While	the	hormone’s	actions	in	the	brain	go	well	beyond	mere	regulatory	effects	on	metabolism51,	it	is	now	becoming	clear	that	central	insulin	signalling	also	has	an	impact	on	peripheral	glucose	homeostasis52.	Further,	a	deficiency	in	insulin	signalling	appears	to	be	an	important	factor	in	the	neurodegenerative	cascade	leading	to	the	clinical	appearance	of	Alzheimer’s	disease53.	There	are	two	main	reasons	to	believe	that	ghrelin	also	plays	a	role	in	the	interplay	of	glucose	homeostasis	and	neurodegeneration.	First,	ghrelin	has	insulinostatic	properties	when	administered	acutely54,	probably	in	order	to	keep	glucose	levels	high	in	a	situation	of	energy	deficiency.	Second,	there	is	a	strong	body	of	evidence	of	ghrelin	being	neuroprotective	in	several	entities	of	neurodegenerative	diseases16,55.	The	latter	led	to	a	study	performed	in	Inga	Kadish’s	lab	showing	that	a	ghrelin	agonist	given	chronically	is	capable	of	reducing	the	Aβ-plaque	load	in	an	Alzheimer’s	disease	mouse	model17.				
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Figure	A:	Example	of	a	W02-staining	for	Aβ-plaques	in	a	heavily	affected	animal	(C57/BL6	APPSwDI	mouse)	
in	study	1	(see	methods	study	1	and	immunohistochemistry	results).				
3.7	Chronic	disease,	chronic	administration:	The	idea	behind	publication	1		With	this	study	in	mind,	we	aimed	at	designing	a	study	looking	into	the	effects	of	a	high	glycemic	index	diet	on	Alzheimer’s	disease	pathology	in	the	same	mouse	model	–	and	the	impact	ghrelin	has	in	this	setting.	If	ghrelin	is	indeed	insulinostatic,	there	is	reason	to	believe	that	it	actually	even	deteriorates	the	possibly	negative	effects	of	a	high	glycemic	index	diet	on	Alzheimer’s	disease	pathology56.	This,	however,	would	contradict	the	findings	of	the	many	studies	showing	the	positive	properties	of	ghrelin	in	
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neurodegenerative	diseases	(see	hypotheses	described	in	publication	1).	At	the	same	time,	neither	the	effects	of	ghrelin	agonist	administration	on	insulin	secretion	and	glucose	tolerance	nor	the	resulting	impact	on	Alzheimer’s	disease	pathology	had	previously	been	addressed	in	a	long-term	treatment	model.	This	is	surprising	as	Alzheimer’s	as	well	as	other	neurodegenerative	diseases	are	intrinsically	chronic	diseases	and	thus,	any	therapeutic	approach	is	necessarily	a	long-term	approach.					 High	glycemic	index	diet	 Control	diet	
Protein	(%	kcal	from)	 20.8	 18.8	
Carbohydrate	(%	kcal	from)	 60.2	 63.9	
Fat	(%	kcal	from)	 19.0	 17.2	
Caloric	density	(kcal/g)	 3.4	 3.8	
Main	carbohydrate	ingredients	 AMIOCA	waxy	maize	starch,	maltodextrin	 Corn	starch,	maltodextrin	
	
Table	C:	Together	with	specialists	from	Ingredion	Inc.	and	Harlan/Teklad,	a	custom	research	high	glycemic	
index	diet	was	developed	–	with	the	amount	of	calories	stemming	from	each	macronutrient	as	well	as	caloric	
density	being	close	to	the	standard	control	diet	(see	methods	study	1).													
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4.	Conclusions		
4.1	Publication	1:	Surprising	results	in	long-term	ghrelin	agonist	treatment		In	our	setting,	a	high	glycemic	index	diet	did	not	deteriorate	performance	in	a	water	maze	task	after	four	months	of	treatment	nor	did	it	worsen	immunohistochemical	parameters	in	an	Aβ-plaque	mouse	model	compared	to	other	groups	on	a	different	diet.	This	may	be	in	part	because	our	mice	were	still	not	old	enough	when	they	were	sacrificed	to	show	a	detrimental	effect	in	these	measures	caused	by	their	sugary	diet	(see	methods	study	1).		Neither	did	we	see	an	improvement	in	immunohistochemical	parameters	after	ghrelin	agonist	treatment	as	in	a	previous	study	with	a	different	design17.		There	are,	however,	two	important	messages	contained	in	the	results	of	this	study:	First,	the	cognitive	enhancement	seen	after	long-term	ghrelin	agonist	treatment	appears	to	be	robust,	that	is	consistent	over	both	studies	in	the	same	mouse	model17,18	and	independent	from	the	feeding	regimen	used.		Second,	the	long-term	effects	of	ghrelin	agonist	treatment	differ	greatly	from	the	short-term	effects	of	ghrelin	(agonist)	treatment	in	measures	such	as	food	intake,	body	weight	development,	body	composition	and,	above	all,	glucose	tolerance	(see	results	and	discussion	study	1).	The	effects	in	weight	development	and	body	composition	–	a	glucose	tolerance	test	was	not	performed	at	that	time	–	seen	in	Dr.	Kadish’s	previous	study	with	the	same	mouse	model	but	different	diets	were	not	as	radical	as	in	the	study	presented	in	this	dissertation.	Nonetheless,	the	weight	gain	effects	that	were	thus	far	regarded	as	typical	of	ghrelin	(agonists)	could	not	be	observed	either.		
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Although	the	possibilities	of	extrapolating	the	results	of	our	study	to	other	mouse	models	or	even	other	mammal	organisms	are	very	limited	–	a	very	specific	mouse	model	with	a	very	specific	diet	and	a	very	specific	ghrelin	agonist	were	used	–	it	should	make	us	sensitive	to	possibly	big	differences	in	the	impacts	of	ghrelin	on	mammal	organisms	depending	on	whether	it	is	give	acutely	or	on	a	long-term	feeding	regimen	(see	discussion	study	1).		How	do	we	explain	the	improvements	in	cognitive	performance	if	no	differences	in	immunohistochemical	endpoints	could	be	detected?	Although	finding	a	precise	answer	to	this	question	resembles	the	search	for	the	notorious	needle	in	a	haystack,	the	positive	effects	of	ghrelin	agonist	treatment	on	glucose	tolerance	hint	in	the	direction	of	insulin	signalling	as	a	possible	endpoint	to	look	at.	The	data	we	found	in	this	respect	–	a	lower	expression	of	p-IRS-1	Ser636,	which	has	been	shown	to	be	associated	with	both	Alzheimer’s	disease	and	diabetes57,	after	ghrelin	agonist	treatment	–	is	far	from	robust	and	fails	to	fully	explain	the	behavioural	changes	we	saw	in	our	sample	of	mice.	Nonetheless,	it	is	little	surprising	and	opens	up	a	new	pathway	of	thinking	when	it	comes	to	explaining	ghrelin’s	beneficial	effects	on	both	glucose	tolerance	and	cognitive	performance.	One	important	finding	that	may	be	seen	as	a	confounder	in	this	study	is	the	higher	level	of	activity	during	the	active	period	in	mice	treated	with	the	ghrelin	agonist	(see	figure	3	of	publication	1).	Therefore,	one	might	regard	the	positive	effects	of	the	ghrelin	agonist	on	cognitive	parameters	as	a	mere	consequence	of	the	already	known	positive	effects	of	exercise	on	cognitive	performance	both	in	rodents	and	humans58,59.	Although	we	regard	this	as	a	valid	limitation	to	the	interpretation	of	our	results,	we	do	not	think	that	exercise	alone	can	explain	our	findings	regarding	food	intake	and	weight	
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gain	after	ghrelin	agonist	treatment.	Nonetheless,	especially	in	future	long-term	studies,	this	possible	confounder	has	to	be	taken	seriously.		
4.2	Publication	2:	What	ghrelin	does	not	do		The	result	of	the	second	study	are,	at	least	as	far	as	behavioural	paradigms	are	concerned,	negative.	The	cognitive	enhancing	effects	we	hypothesized	but	could	not	detect	appear	to	be	either	utterly	absent	or,	more	likely,	limited	to	tasks	involving	more	salient	stimuli	relevant	to	a	person	in	a	state	of	hunger46.	The	fMRI	results	appear	to	be	more	robust	but	a	lack	of	behavioural	results	makes	any	interpretation	relatively	difficult.	Despite	the	overall	negative	results	of	this	study,	a	number	of	conclusions	and	ideas	for	future	studies	can	be	drawn	from	it.	First	of	all,	a	study	with	a	similar	design	but	more	salient	stimuli	could	look	into	the	difference	of	memory	performance	for	food	and	non-food	items.	Although	our	study	failed	to	show	significant	differences,	this	still	remains	a	promising	approach	which	could	help	to	further	define	the	role	ghrelin	has	to	play	in	the	“belly-brain-link”	described	above.	Second,	with	the	fMRI	BOLD	signal	essentially	relying	on	a	vascular	response	and	with	the	vascular	contributions	to	the	development	of	Alzheimer’s	and	other	forms	of	dementia60,	it	should	be	asked	to	what	extent	ghrelin	could	be	able	to	selectively	improve	blood	flow61,	oxygenation	and	consequently	metabolic	integrity	in	brain	areas	relevant	to	memory	formation.	Depending	on	the	model	organism	and	the	technique	used,	a	study	addressing	this	question	may	find	interesting	results	in	a	short	term	as	well	as	a	long-term	paradigm.	
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Further,	also	thinking	of	the	results	from	study	1,	the	long-term	effects	of	ghrelin	and	its	agonists	on	glucose	homeostasis,	weight	development	and	cognition	need	to	be	thoroughly	defined.	As	some	agonists	will	probably	soon	be	used	in	larger	samples	of	patients	for	chronic	conditions	such	as	cancer	cachexia62,	it	would	be	both	relatively	simple	and	highly	important	to	include	these	endpoints	in	large-scale	clinical	trials.	As	the	current	evidence	suggests	that	ghrelin	(agonists)	have	both	short-term	and	long-term	cognitive	enhancing	effects	at	least	in	rodents,	it	should	be	asked	what	effect	is	more	robust	and	reliable.	To	what	extent	are	the	cognitive	enhancing	effects	of	the	early	studies	with	ghrelin,	often	given	ICV4	due	to	a	state	of	arousal	more	or	less	independent	of	the	substance	administered?	In	part,	this	question	is	answered	by	the	efficacy	of	other	routes	of	administration	(see	above).	Are	the	long-term	results	replicable	in	other	(non-pathological)	mouse	models,	rats	and	possibly	even	primates	or	are	they	rather	restricted	to	a	very	specific	setting?	And,	as	a	last	point,	it	needs	to	be	asked	what	relevance	studies	using	supraphysiologically	high	levels	of	ghrelin	can	have	in	everyday	life	–	both	for	humans	as	well	as	other	mice	and	other	mammals.	What	natural	secretion	pattern	does	ghrelin	show	in	long-term	settings	involving	situations	of	exercise,	different	food	compositions	and	different	rhythms	of	food	intake	and	sleep?	Current	studies	looking	at	the	circadian	character	of	ghrelin	secretion	are	already	following	this	train	of	thought28.	Are	there	differences	between	small	and	large	animals	or	between	small	and	large	specimens	of	the	same	species,	also	thinking	of	ghrelin’s	character	as	a	growth	hormone	secretagogue?	What	exactly	happens	to	ghrelin	and	insulin	signalling	(and	essentially	the	nutrients	and	substances	for	whose	regulation	our	bodies	synthesize	these	hormones	such	as	glucose,	proteins	and	fatty	acids)	at	the	very	moment	the	body	adapts	
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to	longer	periods	of	fasting	or,	almost	more	relevantly,	to	prolonged	periods	of	overeating?		How	can	we	define	the	course	of	anorexia	nervosa63,	bulimia	nervosa64	and	obesity65	in	terms	of	ghrelin	(and	insulin)	signalling9	and	possibly	develop	pharmaceutical	ways	to	prevent	the	patient	from	crossing	a	“point	of	no	return”?	And,	with	all	the	questions	asked	in	the	last	paragraph:	What	exactly	is	cognition	in	the	different	settings	and	how	is	it	affected?	With	regard	to	the	complexity	of	the	ghrelin	system,	verbal	accuracy	amongst	researchers,	a	clear	differentiation	of	what	aspect	of	cognition	is	examined	in	relation	to	what	exact	part	of	ghrelin	signalling	will	be	crucial	in	future	ghrelin	research.	With	ghrelin	and	its	agonist	still	being	at	a	relatively	early	stage	of	widespread	clinical	use,	we	still	have	a	chance	to	better	understand	ghrelin’s	role	and	relevance	in	human	and	other	organisms	as	well	as	its	delicate	interactions	with	other	hormonal	systems	before	we	try	to	interfere	with	it	therapeutically.											
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5.1	Abstract		The	orexigenic	hormone	ghrelin,	a	potential	antagonist	of	the	insulin	system,	ensures	sufficient	serum	glucose	in	times	of	fasting.	In	the	race	for	new	therapeutics	for	diabetes,	one	focus	of	study	has	been	antagonizing	the	ghrelin	system	in	order	to	improve	glucose	tolerance.	We	provide	evidence	for	a	differential	role	of	a	ghrelin	agonist	on	glucose	homeostasis	in	an	Alzheimer’s	disease	mouse	model	fed	a	high–glycemic	index	diet	as	a	constant	challenge	for	glucose	homeostasis.	The	ghrelin	agonist	impaired	glucose	tolerance	immediately	after	administration	but	not	in	the	long	term.	At	the	same	time,	the	ghrelin	agonist	improved	spatial	learning	in	the	mice,	raised	their	activity	levels,	and	reduced	their	body	weight	and	fat	mass.	Immunoassay	results	showed	a	beneficial	impact	of	long-term	treatment	on	insulin	signaling	pathways	in	hippocampal	tissue.	The	present	results	suggest	that	ghrelin	might	improve	cognition	in	Alzheimer’s	disease	via	a	central	nervous	system	mechanism	involving	insulin	signaling.	
	
Supported	in	part	by	NIH	grants	R01AG043972,	P30DK056336	and	P30NS47466.	The	
opinions	expressed	are	those	of	the	authors	and	do	not	necessarily	represent	those	of	the	
NIH	or	any	other	organization.	 	
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5.2	Introduction		Ever	since	the	discovery	of	ghrelin	as	a	ligand	of	the	growth	hormone	secretagogue	receptor	in	19992,	our	understanding	of	the	versatile	role	of	ghrelin	in	mammals	has	constantly	expanded.	The	characterization	of	ghrelin	has	spanned	its	actions	as	an	orexigenic	hormone	leading	to	weight	gain	and	adiposity	in	rodents3,66,	to	the	stimulation	of	appetite	in	humans67,	its	impacts	on	cognitive	processes	in	rodents4,7	and	humans46,68,69,	and	its	role	as	a	neuroprotective	agent	in	neurodegenerative	diseases8,16,17,70,71.	Ghrelin’s	involvement	in	glucose	metabolism	became	apparent	very	early72,73,	with	evidence	for	a	differential	role	of	des-acyl	ghrelin74,75.	Recently,	many	groups	have	focused	on	the	interactions	of	ghrelin	with	the	insulin	system	in	humans54,69.	Antagonizing	the	insulinostatic	ghrelin	system	has	repeatedly	been	suggested	as	a	novel	mechanism	by	which	to	improve	glucose	homeostasis	in	humans.	However,	to	our	knowledge,	none	of	the	studies	of	the	interactions	of	ghrelin	with	glucose	homeostasis	have	addressed	the	long-term	impact	of	ghrelin	administration	on	a	mammal.		 Our	group	showed	previously	that	administration	of	a	ghrelin	agonist	leads	to	improved	cognition	and	improved	markers	of	pathology	in	an	Alzheimer’s	disease	mouse	model,	even	in	the	absence	of	caloric	restriction17.	The	pathophysiological	correlations	between	Alzheimer’s	disease,	impaired	glucose	metabolism,	and	diabetes	are	well	established76–78,	and	elevated	serum	glucose	levels	have	been	shown	to	be	an	independent	risk	factor	for	dementia	in	humans79.	In	the	present	study,	therefore,	we	aimed	to	investigate	the	long-term	effects	of	a	ghrelin	agonist	given	for	4	months	on	Alzheimer’s	disease	pathology,	cognition,	and	metabolism	in	the	same	mouse	model	fed	a	high–glycemic	index	(GI)	diet	as	a	constant	challenge	for	glucose	homeostasis.	We	
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hypothesized	to	see	either	(i)	a	detrimental	effect	of	ghrelin	agonist	treatment	in	combination	with	this	diet	on	cognitive	and	metabolic	endpoints	owing	to	interference	with	insulin	signaling	and	consequently	higher	overall	blood	glucose	levels	or	(ii)	a	protective	effect	as	seen	in	our	previous	study	via	a	thus	far	unknown	mechanism.		
5.3	Results		
5.3.1	Ghrelin	agonist	acts	as	a	long-term	cognitive	enhancer	in	spatial	learning		Other	groups	have	previously	reported	increased	levels	of	anxiety	in	neonatal	chicks	and	rats	in	the	open	field	test	after	ghrelin	administration4,5.	In	several	preliminary	tests	we	performed	to	exclude	any	a	priori	differences	between	groups,	we	did	not	observe	any	statistically	significant	differences	between	groups	in	categories	such	as	anxiety	or	exploration	activity	(open	field,	zero	maze,	dark-light-box;	see	methods;	data	not	shown).	We	also	did	not	detect	any	significant	group	differences	in	performance	in	an	object	recognition	task,	which	had	been	observed	to	be	improved	by	short-term	ghrelin	treatment	by	another	research	group10.		
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Figure	1:		Ghrelin-agonist-treated	animals	performed	better	in	a	water	maze	test.	They	showed	a	faster	
learning	curve	than	did	the	group	fed	a	high-GI	diet	alone.	Intra-day	differences	between	high-GI	and	high-GI	
+	ghrelin	agonist	groups	were	significant	for	day	3	((a),	one-way	ANOVA	followed	by	post-hoc	Tukey’s	
multiple	comparisons	test,	p=0.026),	an	Area-Under-The-Curve	(AUC)-comparison	for	the	graphs	in	(a)	
revealed	that	ghrelin	agonist	treated	animals	showed	a	strong	tendency	to	perform	better	over	the	entire	
experiment	((c),	p=0.061,	one-way	ANOVA/Tukey’s).	During	probe	trials	(time	to	first	entry	in	the	correct	
quadrant),	the	difference	between	high-GI	and	high-GI	+	ghrelin	agonist	were	significant	at	tendency	level	
only	((b),	p=0.096	for	high	GI	vs.	high	GI	+	ghrelin	agonist,	p=0.054	for	high	GI	+	ghrelin	agonist	vs.	controls,	
one-way	ANOVA/Tukey’s).	Bars	indicate	SEM.	
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Among	the	three	study	groups	(the	group	fed	a	high-GI	diet,	the	group	fed	a	high-GI	plus	ghrelin	agonist,	and	the	control	group,	which	was	fed	an	AIN-93G	purified	diet),	the	group	fed	a	high-GI	diet	plus	ghrelin	agonist	showed	the	best	memory	performance	in	the	water	maze	(figure	1).	Both	in	its	learning	dynamics	in	the	course	of	the	test	days	and	in	its	performance	in	the	probe	trial,	this	group	outperformed	the	other	groups.	However,	the	group	fed	a	high-GI	diet	was	not	impaired	in	its	cognitive	performance	compared	with	the	control	group	as	we	originally	hypothesized.	
	
5.3.2	Ghrelin	agonist	does	not	significantly	affect	Aβ	plaque	load	or	microglia	activation		In	a	previous	study	we	reported	a	positive	influence	of	ghrelin	on	Alzheimer’s	disease	pathology	markers	such	as	Aβ	plaque	load	(human	Aβ4-10;	see	methods)	and	activated	microglia17.	In	the	current	study,	however,	we	did	not	observe	any	significant	differences	between	the	treatment	groups	in	either	of	these	immunohistochemical	endpoints	in	the	stratum	oriens	and	dentate	gyrus	of	the	dorsal	hippocampal	area	(figures	2,	(a)	and	(b)).	Because	the	olfactory	epithelium	has	been	shown	to	be	involved	at	an	early	stage	in	Alzheimer’s	disease80,	we	included	the	olfactory	bulb	in	our	immunohistochemical	measurements.	Microglia	activation	in	the	olfactory	bulb	was	less	in	the	group	fed	a	high-GI	diet	plus	ghrelin	agonist	than	in	the	group	fed	a	high-GI	diet	alone	(p=0.057,	figure	2,	(c)).	The	Aβ	plaque	load	in	the	olfactory	bulb,	however,	did	not	differ	significantly	between	these	groups	as	measured	in	a	grayscale	density	assessment	(figure	2,	(c);	see	methods).	Other	research	groups	have	reported	an	increased	number	of	doublecortin	(DCX)-positive	cells	after	ghrelin	treatment	in	the	hippocampus	of	2-month-old	5XFAD	mice81.	We	did	not	observe	any	significant	differences	between	groups	in	DCX-positive	cell	count	in	the	dentate	gyrus	(data	not	shown).	
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Figure	2:		
Neither	markers	for	activated	microglia	(IBA,	top	row)	nor	for	Aβ-load	(W02,	lower	row)	were	significantly	
different	after	long-term	ghrelin	agonist	treatment	in	the	dentate	gyrus	(a)	and	stratum	oriens	(b).	Only	the	
level	of	activated	microglia	in	the	olfactory	bulb	of	ghrelin-agonist-treated	animals	showed	a	tendency	to	be	
lower	than	in	animals	fed	the	high-GI	diet	alone	((c),	Kruskal-Wallis	test,	followed	by	post-hoc	Dunn’s	
multiple	comparisons	test,	p=0.057).	Bars	indicate	SEM.	
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5.3.3	Long-term	ghrelin	agonist	treatment	leads	to	less	weight	gain,	less	overall	food	
consumption,	and	more	activity		Ghrelin	and	its	agonists	lead	to	overeating	and	obesity	when	food	intake	is	unlimited3,82.	Interestingly,	the	group	fed	a	high-GI	diet	plus	ghrelin	agonist	did	not	gain	as	much	weight	as	did	the	other	treatment	groups	(figure	3,	(a)).	Only	weight	gain	in	the	two	groups	not	treated	with	the	agonist	was	highly	significant	(figure	3,	(a),	p=0.009	for	high-GI	vs.	high	GI	+	ghrelin	agonist	group,	p=0.015	for	controls	vs.	high-GI	+	ghrelin	agonist	group,	ANOVA/Tukey’s).	Of	note,	the	increase	in	fat	mass	was	particularly	low	in	the	group	fed	a	high-GI	diet	plus	ghrelin	agonist	(figure	3,	(b)).		Because	the	food	consumption	of	agonist-treated	animals	was	limited	to	the	average	amount	consumed	by	the	group	fed	the	high-GI	diet	alone	(see	methods),	overeating	triggered	by	the	ghrelin	agonist	was	not	possible	in	this	group.	We	observed	a	strong	feeding	response	in	our	animals	after	the	administration	of	the	ghrelin	agonist;	however,	the	attempt	to	quantify	this	response	in	CLAMS	metabolic	cage	measurements	failed.	The	mice	did	not	tolerate	the	procedure,	mainly	because	of	an	accidentally	shifted	dark-night	cycle.	As	a	proof	of	concept,	we	have	included	CLAMS	data	from	previous	studies	with	C57/BL6	mice	that	clearly	show	the	immediate	feeding	response	after	the	administration	of	the	same	agonist	LY444711	(figure	3,	(e)	and	(f)).		Interestingly,	daily	recording	of	food	intake	in	the	group	fed	a	high-GI	diet	plus	ghrelin	agonist	over	8	weeks	showed	that	the	animals	did	not	consume	the	full	amount	of	food	given	to	them	daily	(figure	3,	(g)).	This	finding	and	the	overall	elevated	activity	levels	in	agonist-treated	animals	compared	with	those	fed	the	high-GI	diet	alone	(p<0.001	for	high-GI/controls	vs.	ghrelin	agonist	treated	group,	ANOVA/Tukey’s,	figure	3,	(d))	can	explain	the	lesser	weight	gain	in	this	treatment	group.	
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Figure	3:		
Over	a	period	of	3	months	((a)-(c),	compare	timepoints	“week	8”	and	“week	21”	of	the	study),	animals	not	
treated	with	the	ghrelin	agonist	gained	significantly	more	weight	than	ghrelin	agonist	treated	animals	((a),	
p=0.009	for	high-GI	group	vs.	ghrelin	agonist	group,	p=0.015	for	controls	vs.	ghrelin	agonist	group,	one-way	
ANOVA/	Tukey’s).	The	same	groups	showed	a	tendency	to	gain	more	fat	mass	((b),	p=0.062	for	high	GI	vs.	
ghrelin	agonist	group,	p=0.069	for	controls	vs.	ghrelin	agonist	group,	one-way	ANOVA/Tukey’s)	than	ghrelin	
agonist	treated	animals.	The	high-GI	group	gained	significantly	more	lean	mass	than	the	ghrelin-agonist	
treated	group	((c),	p=0.048),	the	controls	showed	a	tendency	((c),	p=0.069,	one-way	ANOVA/Tukey’s).	
Activity	levels	during	the	mice’s	active	period	(measurements	taken	in	week	21)	were	higher	in	ghrelin-
agonist-treated	animals	than	in	the	high-GI	and	control	diet	groups	((d),	p<0.001	for	both	comparisons,	one-
way	ANOVA/Tukey’s).	Immediately	after	administration,	the	ghrelin	agonist	led	to	significantly	higher	food	
intake	during	the	2	subsequent	hours	((e),	p=0.045	for	AUC	between	gray	arrows	in	(f),	data	for	a	sample	of	
12-month-old	C57/BL6	mice	from	a	different	study,	t-test	for	unpaired	samples).	However,	cumulative	food	
intake	as	measured	for	an	entire	day	hardly	ever	reached	the	maximum	of	food	assigned	to	ghrelin-agonist-
treated	animals	as	indicated	by	the	gray	lines	((g),	days	refer	to	the	period	while	food	intake	was	recorded).	
Bars	indicate	SEM.	
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5.3.4	Long-term	ghrelin	agonist	treatment	does	not	impair	glucose	tolerance		In	order	to	characterize	the	impacts	of	a	high-GI	diet	and	long-term	ghrelin	agonist	treatment	on	glucose	metabolism,	we	performed	an	oral	glucose	tolerance	test	after	3	and	4	months	of	treatment.	Baseline	glucose	levels	after	6	hours	of	fasting	(see	methods)	did	not	differ	significantly	between	the	groups	in	either	test	(figure	4,	(a)).		A	comparison	of	the	area	under	the	time	curve	(AUC)	for	both	high-GI	groups	as	well	as	the	controls	during	the	first	test,	which	was	performed	shortly	before	the	daily	administration	of	the	ghrelin	agonist,	did	not	reveal	any	differences.	This	suggests	that	neither	the	high-GI	diet	on	its	own	nor	in	combination	with	long-term	ghrelin	agonist	treatment	impaired	glucose	tolerance	(figure	4,	(b)).	In	order	to	clarify	the	ghrelin	agonist’s	short-term	effects	on	glucose	homeostasis,	in	the	second	glucose	tolerance	test,	we	treated	animals	with	the	ghrelin	agonist	immediately	before	administering	the	glucose	load.	In	this	experiment,	the	agonist-treated	animals	showed	a	significantly	higher	AUC	than	during	the	first	test	(p=0.010,	t-test	for	paired	samples,	figure	4,	(b)),	whereas	the	mean	AUC	for	the	other	groups	did	not	change	significantly.	There	were	also	no	significant	differences	in	the	second	test	between	groups.	This	result	illustrates	the	differential	effect	of	the	ghrelin	agonist	on	short-term	and	long-term	glucose	homeostasis.	We	expected	to	see	overall	lower	endogenous	acyl	ghrelin	levels	after	long-term	treatment	with	a	ghrelin	agonist,	hypothesizing	that	artificially	high	ghrelin	levels	over	a	long	period	of	time	would	lead	to	a	down-regulation	of	endogenous	production	of	the	active	peptide.	However,	both	serum	acyl	and	desacyl	ghrelin	levels	as	measured	after	a	6-hour	fast	were	significantly	higher	in	the	group	fed	a	high-GI	diet	plus	ghrelin	agonist	than	in	the	group	fed	the	high-GI	diet	alone	(figure	4,	(f)	and	(h)).	A	cross-reactivity	in	the	assay	between	ghrelin	agonist	and	endogenous	ghrelin	cannot	be	excluded	with	
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absolute	certainty	but	appears	both	highly	unlikely	and	probably	insignificant	because	the	last	administration	of	the	agonist	took	place	24	hours	before	the	blood	samples	were	taken.	Insulin	levels	measured	at	the	same	time	did	not	differ	significantly	between	groups	(figure	4,	(g)).		It	could	be	speculated	that	the	long-term	ghrelin	agonist	treatment	led	to	a	lower	amount	of	ghrelin	receptors	in	peripheral	tissues,	requiring	higher	circulating	active	ghrelin	levels	for	the	same	metabolic	effects.	However,	the	differential	analysis	of	peripheral	tissues	for	endpoints	relevant	to	insulin	and	ghrelin	signaling	was	beyond	the	scope	of	this	project.	Possible	future	results	of	currently	ongoing	measurements	will	be	discussed	in	a	separate	publication.	
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Figure	4:		
Baseline	blood	glucose	levels	after	a	six	hours	fasting	period	did	not	differ	significantly	between	treatment	
groups	((a),	one-way	ANOVA/Tukey’s).	Overall,	the	results	of	an	oral	glucose	tolerance	test	were	not	
influenced	by	long-term	ghrelin	agonist	treatment	(AUC	=	area	under	the	curve,	(b)-(e)).	In	the	second	test,	
animals	from	the	high	GI	+	ghrelin	group	were	treated	with	the	ghrelin	agonist	immediately	before	the	
glucose	tolerance	test	and	showed	significantly	higher	blood	glucose	levels	than	in	the	first	test	(p=0.010,	t-
test	for	paired	samples,	(b)	and	(d)).	Both	serum	acyl	((f),	p=0.020,	Kruskal-Wallis/Dunn’s)	and	desacyl	
ghrelin	((h),	p=0.020,	ANOVA/Tukey’s)	levels	measured	after	a	6-hour	fasting	period	were	significantly	
higher	in	animals	treated	with	the	ghrelin	agonist.	There	were	no	significant	differences	in	serum	insulin	
levels	in	the	same	samples	((g),	one-way	ANOVA/Tukey’s	4.7).	Bars	indicate	SEM.	
	
	
	
	
5.3.5	Ghrelin	agonist	treatment	beneficially	influences	central	insulin	signaling	pathway		Because	other	authors	suggested	an	involvement	of	the	tumor	necrosis	factor	α	(TNF-α)/c-Jun	n-terminal	kinase	(JNK)	pathway	in	Alzheimer’s	disease	triggered	by	Aβ-oligomers57,	we	measured	TNF-α,	pSAP-JNK,	and	phosphorylated	insulin	receptor	substrate	1	(p-IRS	Ser636)	as	well	as	synaptophysin	and	PSD-95	as	synaptic	markers	in	hippocampal	brain	tissue	from	the	groups	fed	the	high-GI	diet	(figure	5).	We	found	a	significant	difference	in	p-IRS	levels	between	the	groups	(fig.	5,	(a),	p=0.039,	nonparametric	Kolmogorov-Smirnov	test),	indicating	a	possible	interaction	of	long-term	ghrelin	agonist	treatment	with	central	insulin	signaling.		There	was	a	moderate	negative	correlation	in	a	linear	regression	analysis	between	behavioral	results	and	p-IRS	levels	for	both	groups	(r=-0.41);	however,	this	correlation	was	not	significant	(p=0.175,	data	not	shown).	We	did	not	observe	any	
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differences	in	structural	synaptic	markers,	neither	presynaptically	(synaptophysin)	nor	postsynaptically	(PSD-95).	Because	there	were	no	group	differences	in	TNF-α	or	JNK-levels,	we	could	not	reproduce	the	TNF-α/JNK	interrelations	in	Alzheimer’s	disease	in	our	mice.			
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Figure	5:		
Animals	treated	with	a	ghrelin	agonist	showed	a	significantly	lower	amount	of	phosphorylated	IRS	(pIRS	
Ser636),	which	has	been	shown	to	be	associated	with	impaired	glucose	tolerance	((a),	p=0.039,	
nonparametric	Kolmogorov-Smirnov	test).	However,	we	did	not	detect	any	significant	differences	in	
hippocampal	tissue	between	the	high	GI	and	high	GI	+	ghrelin	agonist	groups	for	synaptophysin	(c),	
pSAP/JNK	(d),	TNF-α	(e)	or	PSD-95	(f).	Bars	indicate	SEM.	
	
	
	
	
5.4	Discussion		Type	2	diabetes	and	Alzheimer’s	type	dementia	are	chronic	diseases;	consequently,	all	symptomatic	treatments	are	intrinsically	long-term.	However,	most	studies	of	the	interactions	of	ghrelin	and	insulin,	which	partly	aimed	to	derive	novel	therapeutic	pathways	in	diabetes,	have	looked	at	fairly	short	time	frames	of	hours,	days,	or	weeks83–
85.	In	our	study,	we	chose	long-term	ghrelin	agonist	administration	in	order	to	model	the	impacts	of	therapeutically	influencing	this	system	in	a	mammal	over	a	period	of	several	months.	First,	we	could	reproduce	the	previously	known	cognitive-enhancing	effects	of	ghrelin	and	ghrelin	agonists8,	and	at	the	same	time	we	showed	that	this	effect	is	seen	even	under	the	influence	of	a	high-GI	diet	despite	the	ghrelin	agonist’s	short-term	insulinostatic	effect.	The	cognitive-enhancing	effects	were	seen	in	the	water	maze	test	(figure	1),	which	is	mainly	a	hippocampus-dependent	spatial	learning	task86.	This	finding	underlines	the	relevance	of	this	ghrelin	agonist’s	cognitive	effects	in	the	Alzheimer’s	type	of	dementia,	which	most	prominently	affects	hippocampal	brain	areas	and	functions.	
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Most	interestingly,	we	could	show	a	long-term	effect	of	ghrelin	agonist	treatment	on	metabolism	that	differed	from	its	short-term	actions	on	food	consumption,	weight	development,	and	glucose	tolerance.	At	the	same	time,	we	observed	the	well-known	short-term	orexigenic	and	insulinostatic	effects	of	this	endogenous	peptide.	These	findings	indicate	a	differential	metabolic	role	of	the	ghrelin	system	in	short-term	and	long-term	treatment	and	call	for	a	further	differentiation	of	ghrelin’s	long	term	role	on	glucose	homeostasis,	e.g.	by	including	glucose	clamp	techniques	in	a	long-term	study	design.	Further,	the	observations	in	metabolic	endpoints	were	made	using	the	ghrelin	agonist	in	combination	with	a	high	glycemic	index	diet.	To	what	extent	the	results	presented	in	this	manuscript	depend	on	this	specific	combination	and	to	what	extent	they	are	also	valid	for	a	combination	of	a	normal	diet	with	a	ghrelin	agonist	will	be	addressed	in	future	and	ongoing	studies.	Given	ghrelin’s	differential	interactions	with	insulin	signaling,	possibly	also	via	mTORC1-dependent	pathways84,87,88,	we	hypothesized	a	potentially	protective	effect	of	ghrelin	agonist	treatment	on	insulin	signaling	in	the	central	nervous	system.	In	agonist-treated	animals,	we	found	a	lower	expression	of	p-IRS-1	Ser636,	which	has	been	shown	to	be	associated	with	both	peripheral	insulin	resistance89,	obesity90	and	Alzheimer’s	disease57.	We	therefore	speculate	that	ghrelin	and	insulin	signaling	in	the	central	nervous	system	are,	to	an	extent,	synergistic.	On	the	one	hand,	the	hormone	reduces	peripheral	glucose	uptake	in	periods	of	fasting,	whereas	on	the	other	hand	it	improves	or	at	least	does	not	reduce	glucose	uptake	in	the	central	nervous	system	in	situations	of	energy	deficiency91.			A	limitation	of	the	interpretation	of	the	present	results	is	that	the	data	are	based	on	a	mouse	model	for	Alzheimer’s	disease	under	the	influence	of	a	very	specific	high-GI	diet.	
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The	latter	might	explain	why	we	could	not	replicate	the	immunohistochemistry	results	of	our	previous	study17.		All	extrapolation	of	these	findings	to	other	animal	models	must	be	done	with	care.	Furthermore,	we	did	not	observe	any	structural	differences	in	immunohistochemical	markers	for	Aβ	plaque	load	or	central	nervous	system	inflammation	or	in	synaptic	markers,	which	essentially	leaves	the	task	of	identifying	an	immediate	correlate	of	cognitive	enhancement	by	ghrelin	to	future	studies.	The	present	findings	do	suggest	that	any	new	therapeutic	approaches	in	both	diabetes	and	neurodegenerative	diseases	that	are	based	on	a	manipulation	of	the	ghrelin	system	must	be	addressed	with	utmost	care.	Counteracting	ghrelin	signaling	for	better	glucose	control	or	enhancing	ghrelin	signaling	in	the	central	nervous	system	for	neuroprotection	and	cognitive	enhancement	are	two	tempting	therapeutic	pathways	in	neuroscience	and	endocrinology.	However,	both	have	to	withstand	long-term	testing	and	the	potentially	contrasting	effects	of	ghrelin	and	ghrelin	agonists	in	peripheral	tissues	and	in	the	brain.		
	
	
Figure	6:		
Timeline	of	the	study	
	
	 54	
5.5	Methods			
5.5.1	Ethics	statement		All	animal	protocols	were	approved	by	the	University	of	Alabama	at	Birmingham	Institutional	Animal	Care	and	Use	Committee	(IACUC).	All	methods	were	carried	out	in	accordance	with	the	approved	guidelines	and	protocols.		
5.5.2	Animals,	diets,	and	treatment		The	study	timeline	is	shown	in	figure	6.	A	total	of	36	male	Tg	APPSwDI	(human	APP	with	Swedish,	Dutch,	and	Iowa	mutations	on	a	C57BL/6	background)	were	raised	under	equal	dietary	conditions	for	2	months.	At	10	weeks	of	age,	the	animals	were	divided	into	three	groups	of	12	animals	each	and	received	a	diet	consisting	of	60%	of	kcal	in	carbohydrates	with	equal	amounts	of	maltodextrin	and	sucrose	plus	either	waxy	maize	starch	(high-GI	diet	groups)	or	AIN-93G	purified	diet	(controls).	For	detailed	diet	composition,	see	the	supplementary	material.	During	the	first	week	of	dietary	acclimatization,	all	animals	received	a	45-mg	sucrose	pellet	daily.	After	that,	the	group	fed	the	high-GI	diet	plus	ghrelin	agonist	received	a	45-mg	sucrose	pellet	containing	1.66%	ghrelin	agonist92	(LY444711;	Eli	Lilly,	Indianapolis,	IN)	every	day	(30mg/kg/day,	parallel	to	our	previous	study17,	dose	determined	according	to	previous	work	by	Giddings	et	al.	2008,	abstract	added	to	supplement);	the	other	groups	continued	to	be	treated	with	sucrose	pellets	as	placebos.	Treatment	took	place	daily	at	the	same	time	between	2:00	and	4:00	pm	during	the	animals’	light	cycle	and	continued	until	the	animals	were	sacrificed	(treatment	period:	week	11	until	week	30).	Staff	watched	all	animals	take	and	eat	the	pellets	and	noted	the	days	when	the	pellet	was	not	consumed.	
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This	was	only	the	case	for	few	animals	during	dietary	acclimatization.	During	the	treatment	period	all	animals	ate	the	pellets.	The	amount	of	food	consumed	by	all	groups	was	measured	every	2	weeks	and	the	threshold	of	food	restriction	for	the	ghrelin-agonist-treated	group	was	set	at	the	average	level	of	food	consumption	of	the	group	fed	the	high-GI	diet	alone.		
5.5.3	Behavioral	and	cognitive	assessments			All	behavioral	and	cognitive	assessments	took	place	between	weeks	22	and	24	(see	fig.	6).	All	tests	took	place	during	the	light	cycle.	Feeding	times	were	not	changed	throughout	the	assessments.	
	
5.5.4	Open	field	test		The	maze	consisted	of	a	42	by	42	cm2	arena	with	clear	sides	(20	cm	high).	The	animal	was	placed	in	the	arena	and	observed	for	4	minutes	with	a	camera-driven	tracker	system	(Ethovision	9.5,	Noldus,	The	Netherlands).	The	arena	was	subdivided	into	the	open	center	area	and	the	sides.	The	system	recorded	the	position	of	the	animal	at	5	frames/s.		
5.5.5	Water	maze		The	water	maze	apparatus	and	procedure	were	described	in	detail	before93.	Briefly,	we	used	a	blue	plastic	pool,	120	cm	in	diameter,	and	a	see-through	round	platform,	10	cm	in	diameter,	located	0.5	cm	below	the	water	surface.	During	days	1	through	5	of	the	testing	period,	the	mice	were	trained	to	find	the	hidden	platform,	which	was	kept	in	a	constant	
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position	throughout	these	5	days.	Three	trials	were	run	per	day;	all	starting	positions	were	used	equally	in	a	pseudo-random	order.	The	mice	were	given	60s	to	find	the	platform	and	10s	to	stay	on	the	platform.	If	the	mouse	did	not	find	the	platform	in	the	assigned	time,	it	was	manually	put	onto	the	platform.	The	inter-trial	interval	during	which	the	mouse	was	placed	in	a	towel-bedded	drying	cage	lasted	1	minute.	Learning	of	the	task	was	evaluated	by	recording	the	latency	time	to	find	the	platform.	At	the	end	of	the	four	trials	on	day	5	of	the	testing	period,	the	mice	were	tested	in	a	60-s	probe	trial	with	no	escape	platform	present.	Mice	that	had	learned	the	platform	position	predominantly	searched	in	the	“correct”	quadrant	of	the	pool	during	the	probe	trial	or	entered	the	correct	quadrant	faster.	Trials	were	recorded	by	using	a	camera-driven	tracker	system	(Ethovision	9.5,	Noldus,	The	Netherlands).		
5.5.6	Zero	maze		For	the	zero	maze	test,	we	used	a	round	maze	with	a	diameter	of	61	cm	designed	for	mice	(SD	Instruments,	San	Diego,	CA).	At	the	beginning	of	the	trial,	all	mice	were	placed	on	the	same	open	part	facing	in	the	same	direction.	Velocity,	distances	moved,	and	time	spent	in	the	open	and	closed	parts	were	recorded	for	4	minutes	by	using	a	camera-driven	tracker	system	(Ethovision	9.5,	Noldus,	The	Netherlands).		
5.5.7	Light-dark-box		We	used	a	custom-built	plastic	light-dark	box	(46.5	cm	length,	22	cm	width,	28x22	cm	light	part,	18.5x22	cm	dark	part).	Time	spent	in	the	light	and	dark	parts	as	well	as	the	number	of	entries	into	the	dark	part	were	recorded	for	5	minutes	by	using	a	camera-
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driven	tracker	system	(Ethovision	9.5,	Noldus,	The	Netherlands).	Mice	were	placed	in	the	light	part	of	the	box	facing	away	from	the	entrance	to	the	dark	part.		
5.5.8	Immunohistochemistry				Animals	were	sacrificed	at	week	30	for	immunohistochemical,	Western	blot,	and	ELISA	analyses.	Mice	were	anesthetized	with	ketamine/xylazine	(100/10	mg/kg)	and	perfused	with	cold	saline.	The	brains	were	removed	and	cut	in	half	sagittally,	and	the	right	hemisphere	of	the	brain	was	placed	in	4%	paraformaldehyde	overnight.	The	left	hemisphere	was	dissected	into	four	pieces	(rostral	cortex,	caudal	cortex,	hippocampus,	and	midbrain/brainstem)	and	stored	frozen	at	-80oC	for	protein	analysis	(ELISA,	Western	blot).	The	right	half	and	the	intact	whole	brains	from	12	animals,	4	per	group,	were	put	in	30%	sucrose	for	cryoprotection,	and	30-μm	thick	coronal	sections	were	cut	on	a	freezing-sliding	microtome.		Sections	from	29	brains	were	stained	for	Aβ	with	the	W0-2	antibody	(human	Aβ4-10;	1:2000;	The	Genetics	Company,	Schlieren,	Switzerland).	Another	series	of	sections	from	the	same	29	brains	was	stained	for	Iba-1	(1:1000;	Wako,	Richmond,	VA)	as	a	marker	for	activated	microglia.	For	Aβ	staining,	sections	were	pretreated	for	30	minutes	in	85°C	sodium	citrate	solution	(pH=6.5).	Following	incubation	with	the	primary	antibody	in	TBS-T	overnight	at	room	temperature,	tissues	were	rinsed	three	times	and	incubated	with	the	appropriate	biotinylated	secondary	antibody	for	2	hours	at	room	temperature.	Sections	were	again	rinsed	three	times	and	put	for	2	hours	with	the	tertiary	antibody,	extra	Avidin-peroxidase.	After	another	three	rinses,	metal-enhanced	DAB	staining	was	used	for	visualization.	For	each	antibody,	all	sections	were	processed	in	one	staining	tray.	All	slides	were	air-dried,	cleared	in	xylene,	and	coverslipped	with	DPX.	
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	ImageJ	software	(NIH	open	source;	http://imagej.nih.gov/ij/)	was	used	to	analyze	the	area	occupied	by	Aβ	and	glial	reactivity	in	stratum	oriens	of	the	dorsal	hippocampus	and	in	the	dorsal	dentate	gyrus.	Images	of	the	appropriate	brain	areas	were	acquired	with	an	Olympus	DP70	digital	camera.	All	images	were	acquired	in	one	session	to	avoid	changes	in	light	levels.	ImageJ	measurements	were	performed	by	a	scientist	who	was	blind	to	the	study	design.	Few	images	had	to	be	excluded	due	to	staining/tissue	preparation	problems	(see	fig.	2).	
	
5.5.9	Oral	glucose	tolerance	test		In	order	to	avoid	a	priori	differences	in	baseline	blood	glucose	levels,	mice	had	no	access	to	food	for	a	period	of	six	hours	before	the	glucose	tolerance	test.	For	the	oral	glucose	tolerance	test,	300	µl	of	a	solution	of	16.7	g	glucose	in	100	ml	of	purified	water	was	administered	directly	into	the	mice’s	stomach	via	gavage	needles.	Blood	samples	were	taken	from	tail	veins	and	immediately	measured	with	the	TRUE2Go	blood	measurement	system94	for	one	baseline	time	point	and	then	after	17,	34,	60,	and	90	min.	The	mice	were	placed	in	a	plastic	retainer	system	during	the	procedure.	One	mouse	was	excluded	from	the	analysis	because	it	did	not	tolerate	the	gavage	process.	
	
5.5.10	Protein	extraction	and	Western	blotting		For	ELISA	and	Western	blots,	brain	tissue	was	homogenized	in	RIPA	(150	mM	NaCl,	0.1%	SDS,	0.5%	sodium	deoxycholate,	1%	NP-40,	50	mM	Tris,	pH	8,	20	mM	NaF,	2	mM	EGTA,	0.5%	levamisole,	1	mM	NaVO4)	plus	protease	inhibitor	cocktail	(p2714	Sigma-Aldrich,	St	Louis,	MO)	by	use	of	the	fast	homogenization	process	Minilys®	(Precellys,	
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Bertin,	France).	After	protein	estimation	with	the	Bradford	method95,	samples	were	diluted	to	an	appropriate	concentration.	For	Western	blotting,	p-IRS	Ser636	antibody	(Santa	Cruz	Biotechnology,	Dallas,	TX),	synaptophysin	antibody	clone	SVP-38	(Sigma-Aldrich,	St	Louis,	MO),	pSAPK/JNK	Thr183/Tyr185	(Cell	Signaling	Technologies,	Danvers,	MA)	and	PSD-95	antibody	(Upstate/Millipore,	Billerica,	MA)	were	used.	After	electrophoresis	and	transfer	to	nitrocellulose,	samples	were	incubated	with	the	primary	antibody	overnight	and	were	then	incubated	with	the	suitable	secondary	antibody	for	90	minutes.	For	measuring	TNF-alpha,	a	commercial	ELISA	kit	was	used	(EMTNFA,	ThermoScientific,	Rockford,	IL).		
5.5.11	Blood	samples		Blood	samples	were	taken	after	a	6-hour	fasting	period	via	intracardial	puncture	from	the	left	ventricle	shortly	before	the	animals	were	perfused.	Samples	of	250	µl	of	blood	were	collected	in	chilled	EDTA	tubes	(Becton,	Dickinson	and	Company,	Franklin	Lakes,	NJ)	that	were	prefilled	with	5	µl	of	200	mM	AEBSF	stock	yielding	a	final	concentration	of	4	mM	AEBSF.	Samples	were	centrifuged	for	20	minutes	at	17000	rpm	and	4°C	and	the	plasma	collected	was	immediately	acidified	with	200	µl	of	1	M	HCl	per	1	ml	of	plasma.	pH	was	adjusted	accordingly	before	ELISA	measurements	for	insulin	and	ghrelin.	Acyl	ghrelin	and	des-acyl	ghrelin	was	measured	with	a	custom-built	2-site	sandwich	ELISA47.	For	the	measurement	of	insulin	a	commercially	available	ELISA	kit	was	used	(EZRMI-13K,	EMD-Millipore,	Billerica,	MA).	
	
	 60	
	
5.5.12	Quantitative	magnetic	resonance	imaging	
	In	vivo	body	composition	(total	body	fat	and	lean	tissue)	of	mice	was	determined	by	using	an	EchoMRI™	3-in-1	quantitative	magnetic	resonance	(QMR)	machine	(Echo	Medical	Systems,	Houston,	TX).	A	system	test	was	performed	by	using	a	known	fat	standard	before	the	measurements	were	taken.		Mice	were	weighed	and	then	placed	into	a	clear	holding	tube	capped	with	a	stopper	that	restricted	vertical	movement	but	allowed	constant	airflow.	The	tube	was	inserted	into	the	machine	and	the	mouse	was	scanned	by	using	Normal	Precision	mode.						
5.5.13	Metabolic	cages		Twenty-four-hour	patterns	of	food	intake,	energy	expenditure	(indirect	calorimetry),	and	physical	activity	were	measured	by	using	CLAMS	(Columbus	Instruments	Inc.,	Columbus,	OH).	This	instrument	also	enforced	the	feeding	regimens	in	an	automated,	computer-controlled	manner.	Body	weight	was	monitored	weekly.		
5.5.14	Activity	measurements			Additional	activity	measurements	over	a	period	of	five	consecutive	light	and	dark	cycles	were	performed	at	week	21	by	using	a	custom-built	infrared-based	beam-breaking	system	that	recorded	horizontal	and	vertical	movements.	Mice	were	placed	in	the	system	in	their	home	cages	with	reduced	bedding	in	order	to	not	disrupt	the	continuous	infrared	measurements.	Only	data	recorded	on	days	2	to	4	were	included	in	the	analysis.		
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5.5.15	Statistical	methods		All	datasets	were	tested	for	Gaussian	distribution	using	a	D’Agostino	&	Pearson	omnibus	normality	test.	Whenever	a	normal	(Gaussian)	distribution	could	be	validly	assumed,	a	one-way	ANOVA,	then	a	post-hoc	Tukey’s	test	for	multiple	comparisons	was	used	to	test	for	significant	differences	between	groups	(referred	to	as	“ANOVA/Tukey’s”).	Nonparametric	samples	were	tested	using	the	Kruskal-Wallis	test	and	Dunn’s	test	for	multiple	comparisons	as	a	post-hoc	test	(referred	to	as	“Kruskal-Wallis/Dunn’s”).	Whenever	only	two	groups	were	involved	in	the	measurements,	differences	were	tested	using	a	t-test	for	paired/unpaired	samples	in	parametric	distributions	or	a	Kolmogorov-Smirnov	test	for	nonparametric	distributions.	Being	aware	of	the	nested	data	problem96,	we	only	compared	values	on	the	same	level	of	analysis	to	decrease	the	likelihood	of	type-1	errors.	All	analyses	were	performed	with	GraphPad	Prism	software	version	6.05	(GraphPad	Software,	Inc.,	La	Jolla,	CA).		
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6.1	Abstract	
	Ghrelin	regulates	energy	homeostasis	in	various	species	and	enhances	memory	in	rodent	models.	In	humans,	the	role	of	ghrelin	in	cognitive	processes	has	yet	to	be	characterized.	Here	we	show	in	a	double-blind	randomized	crossover	design	that	acute	administration	of	ghrelin	alters	encoding-related	brain	activity,	however	does	not	enhance	memory	formation	in	humans.	Twenty-one	healthy	young	male	participants	had	to	memorize	food-	and	non-food-related	words	presented	on	a	background	of	a	virtual	navigational	route	while	undergoing	fMRI	recordings.	After	acute	ghrelin	administration,	we	observed	decreased	post-encoding	resting	state	fMRI	connectivity	between	the	caudate	nucleus	and	the	insula,	amygdala,	and	orbitofrontal	cortex.	In	addition,	brain	activity	related	to	subsequent	memory	performance	was	modulated	by	ghrelin.	On	the	next	day,	however,	no	differences	were	found	in	free	word	recall	or	cued	location-word	association	recall	between	conditions;	and	ghrelin’s	effects	on	brain	activity	or	functional	connectivity	were	unrelated	to	memory	performance.	Further,	ghrelin	had	no	effect	on	a	cognitive	test	battery	comprising	tests	for	working	memory,	fluid	reasoning,	creativity,	mental	speed,	and	attention.	In	conclusion,	in	contrast	to	studies	with	animal	models,	we	did	not	find	any	evidence	for	the	potential	of	ghrelin	acting	as	a	short-term	cognitive	enhancer	in	humans.				
	
	
	
	
	 65	
6.2	Highlights	
	
- Effects	of	ghrelin	on	memory	for	food-related	words-location	associations	were	tested.	
- Functional	connectivity	during	post-encoding	rest	was	altered	after	ghrelin	injection.	
- Acute	ghrelin	administration	had	no	behavioral	effects	on	long-term	memory	retention.	
- Acute	ghrelin	administration	had	no	behavioral	effects	on	several	other	cognitive	tasks.	
- Ghrelin’s	effects	on	memory	markedly	differ	between	animal	models	and	human	subjects.	
	
	
6.3	Introduction		The	orexigenic	peptide	ghrelin	is	involved	in	appetite	regulation3,9,	but	also	influences	a	number	of	cognitive	functions	in	rodent	models,	such	as	fear	learning,	object	recognition	and	spatial	learning1,4,10,97.	The	hippocampus	appears	to	be	a	central	structure	in	ghrelin’s	effects	on	memory,	with	the	peptide	leading	to	a	lower	threshold	for	long	term	potentiation	in	the	dentate	gyrus	and	to	an	increase	in	hippocampal	spine	synapse	density7.	In	animal	models	of	neurodegenerative	diseases	and	age-related	memory	decline,	ghrelin	appears	to	exert	a	neuroprotective	effect16–18.		Due	to	its	dual	role	in	appetite	regulation	and	hippocampus-related	memory	formation,	an	evolutionary	role	of	ghrelin	in	foraging	processes	was	suggested:	ghrelin	might	support	learning	of	food-associated	locations98,99.	In	humans,	effects	of	ghrelin	on	
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appetite-	and	memory-related	brain	regions	have	been	reported46,68,69,	however,	the	specific	role	of	ghrelin	in	human	cognition	is	yet	to	be	defined1,8.	Studies	on	the	association	between	ghrelin	serum	levels	and	cognitive	function	in	healthy	and	pathological	aging	have	been	rather	contradictory	so	far14,71,100,101.	Also	for	younger	human	subjects,	inconclusive	results	have	been	reported	for	the	role	of	ghrelin	in	memory	processing:	memory	for	food-	compared	to	non-food-related	pictures	was	enhanced	after	administration	of	ghrelin	in	a	simple	recognition	paradigm46,	whereas	nocturnal	ghrelin	administration	had	no	positive	effect	on	sleep-related	consolidation	of	a	simple	motor	learning	task102.	Effects	of	ghrelin	on	more	complex	cognitive	processes	including	encoding	or	consolidation	of	hippocampus-dependent	memories	of	spatial	or	verbal	information	have	not	been	studied	yet.					 In	this	study,	21	healthy	young	male	participants	performed	two	subsequent	runs	of	a	spatial-verbal	learning	task	while	undergoing	functional	magnetic	resonance	imaging	(fMRI).	They	had	to	learn	food	and	non-food	words	presented	on	the	background	of	a	spatial	navigation	environment	(figure	1).	After	each	run,	acyl	ghrelin	or	placebo	was	administered	in	a	double-blind,	randomized,	placebo-controlled	within-subject	design,	thereby	testing	ghrelin	effects	on	both	pure	consolidation	(pre-injection	encoding	run)	and	encoding	(post-injection	encoding	run)	processes.	Memory	performance	was	tested	one	day	later	in	both	a	location-independent	free	recall	task	and	a	cued	location-word	association	recall	task	using	screenshots	of	the	potential	word	presentation	locations	as	spatial	cues.	Immediately	before	and	after	the	encoding	runs,	participants	underwent	a	resting	state	fMRI	scan.		Our	hypothesis	was	that	ghrelin	would	enhance	both	memory	encoding	and	consolidation,	particularly	for	food-related	information	associated	with	spatial	locations.	
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We	further	hypothesized	that	these	memory-enhancing	effects	would	be	reflected	by	specific	activation	changes	in	appetite-	and	memory-related	brain	regions	such	as	the	orbitofrontal	cortex,	insula,	nucleus	caudatus,	nucleus	accumbens,	amygdala,	and	hippocampus,	both	in	task-related	and	resting	state	fMRI.	In	addition,	we	exploratively	tested	the	effects	of	ghrelin	on	a	cognitive	test	battery	including	working	memory,	fluid	reasoning,	creativity,	mental	speed	and	attention	tasks.							
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Figure	1:	Overview	of	the	test	protocol.	All	21	participants	performed	the	schedule	twice	in	a	double-blind,	
randomized,	placebo-controlled	within-subject	design.	One	hour	after	a	standardized	lunch,	two	encoding	
runs	were	performed	under	fMRI	conditions,	with	intravenous	ghrelin	(or	placebo)	administration	shortly	
before	the	second	run.	Before	the	first	and	after	the	second	run,	an	eyes-closed	resting	state	scan	(rs-fMRI)	
was	recorded.	Immediately	after	the	inside-fMRI	sessions,	a	second	dose	of	ghrelin	(or	placebo)	was	given	and	
participants	underwent	a	cognitive	test	battery.	Memory	performance	was	tested	one	day	after	encoding	
with	free	word	recall	and	cued	location-word	association	recall.	
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6.4	Materials	and	Methods	
	
6.4.1	Participants		Twenty-one	male,	healthy,	right-handed	volunteers	at	the	age	of	23±3	years	(mean±SD,	range:	20-30)	years	and	with	a	bodyweight	of	72±7	kg	(range:	60-80	kg)	participated	in	our	study.	Their	health	status	was	confirmed	with	a	medical	screening	including	psychiatric	interview;	blood	screening	(full	blood	count,	urea	and	electrolytes,	liver	function	parameters,	thyroid	function	parameters,	inflammatory	markers);	urine	screening	for	infections	and	drugs;	comprehensive	questionnaire	covering	eating	and	sleeping	habits	and	intake	of	alcohol	and	caffeine,	and	assessment	of	verbal	competence	via	a	standardized	German	vocabulary	test	(MWT-B103).		Exclusion	criteria	were	as	follows:	1)	irregular	eating	patterns	or	dietary	restraints	including	vegetarian/vegan/lactose-free	or	non-Western	diet;	2)	history	of	or	ongoing	inflammatory,	degenerative,	neoplastic,	endocrine,	metabolic,	cardiovascular,	neurological	or	psychiatric	disease	or	serious	injuries;	3)	history	of	or	ongoing	drug	abuse;	4)	irregular	chronobiological	rhythm	including	shift	work	or	late-night	work;	5)	ferromagnetic	objects	inside	the	body,	claustrophobia	or	other	conditions	that	are	not	compatible	with	fMRI	procedures;	6)	non-right	handedness	according	to	the	Edinburgh	Handedness	Inventory;	7)	non-native	German	language	use.	For	a	period	of	one	week	before	the	first	test	block	and	until	the	last	test	block,	participants	were	asked	to	stick	to	a	three-meals-a-day	rhythm.	During	test	blocks,	participants	were	asked	to	completely	refrain	from	caffeine	and	alcohol	consumption.	Ethical	approval	was	granted	by	the	ethics	committee	of	the	University	of	Munich.	Accordingly,	all	participants	gave	written	informed	consent.		
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6.4.2	Experimental	design	and	procedures		Participants	were	tested	in	a	randomized,	placebo-controlled,	within-subject	crossover	design.	All	participants	completed	two	two	three-day	test	blocks	(each	consisting	of	a	pre-test,	a	learning	trial	and	a	re-test;	see	figure	1),	which	were	about	two	weeks	(14±4	days)	apart.	The	nights	in	between	the	test	days	were	spent	at	home.	On	pre-test	days,	we	explained	the	general	procedure	of	the	main	learning	trials	to	our	participants	in	order	to	avoid	unnecessary	delays	particularly	after	the	time-sensitive	administration	of	ghrelin.		During	the	main	test	day,	participants	arrived	at	our	institute	at	09.00	a.m.	with	no	previous	breakfast.	Right	after	arrival,	a	standard	venous	cannula	(18G	or	21G,	B.Braun,	Germany)	was	inserted	into	an	antecubital	vein.	Via	this	cannula,	5ml	of	blood	were	taken	every	60	min,	during	the	in-scan	learning	session	and	during	the	cognitive	test	battery,	a	blood	sample	was	taken	every	15	min	(figure	1).	The	blood	was	first	filled	into	tubes	containing	150µg	of	Aprotinin/150µg	EDTA	and	put	on	ice	for	a	maximum	of	60	min	before	centrifugation	and	freezing	of	the	serum	samples.	In	order	to	prevent	the	blood	in	the	cannula	from	clotting,	participants	received	a	constant	infusion	of	NaCl	0,9%	(B.Braun,	Germany)	with	400	I.U./500ml	NaCl	of	high	molecular	weight	heparin	(Ratiopharm,	Germany)	at	a	controlled	speed	of	50-70ml	per	hour,	reaching	a	total	of	500	–	700	ml	per	test	day.	Serum	ghrelin	levels	were	measured	via	radioimmunoassay	by	the	Max	Planck	Institute	of	Psychiatry	clinical	chemistry	core	unit	(Ghrelin	active	RIA	kit,	DRG	Instruments	GmbH,	Marburg,	Germany).	Volunteers	received	a	standard	breakfast	of	two	wheat	rolls,	butter	and	jam,	a	small	sausage	and	200ml	of	orange	juice	(in	total	approx.	520kcal/2200kJ,	proteins	11g,	fat	21g,	carbohydrates	70g)	right	after	intravenous	catheterization,	and	a	standard	lunch	of	turkey	steak	with	mushroom	sauce,	boiled	rice	and	vegetables	plus	a	chocolate	
	 71	
pudding	as	a	desert	(in	total	approx.	550kcal/2300kJ,	proteins	27g,	fat	13g,	carbohydrates	80g)	between	12.00	and	12.30	p.m.	Water	was	offered	ad	libitum	to	participants	throughout	the	entire	test	day.	All	participants	reported	sufficient	satiety	levels	after	lunch.	Before	the	beginning	of	the	in-MRI	learning	sessions	at	around	1.00	p.m.,	a	45mins	break	was	taken	beginning	at	the	start	of	lunch.	The	time	between	breakfast	and	lunch	was	filled	with	a	movie.	All	trainings	and	tests	were	performed	in	the	same	rooms	supervised	by	the	same	lab	personell.	Before	the	second	encoding	session,	participants	received	a	semi-bolus	of	100µg	acyl	ghrelin	(Bachem,	Switzerland)	diluted	in	5ml	aqua	ad	injectabilia	(B.Braun,	Germany)	or	a	placebo	of	5ml	NaCl	0,9%	(B.Braun,	Germany).	The	ghrelin	dose,	representing	a	quantity	in	the	middle	of	the	spectrum	given	in	previous	studies32,40,	was	given	over	a	period	of	2-3	min,	injecting	1ml	of	the	solution	every	30-45	sec.	To	avoid	losing	any	ghrelin	in	the	blood	withdrawal	system,	the	volume	of	the	tubes	was	measured	in	advance	and	pre-filled	with	ghrelin	solution	before	the	30-45	sec	injection	intervals	were	started	and	flushed	with	several	milliliters	of	saline	right	after	the	ghrelin	injection.	There	was	a	delay	of	about	10	min	from	the	end	of	the	injection	period	until	the	beginning	of	the	second	encoding	session	in	order	to	ensure	a	sufficient	central	bioavailability	during	the	learning	process.	Due	to	acyl	ghrelin’s	short	half-life	time	of	about	8-12	min104,105,	after	the	second	resting	state	scan	we	injected	another	100µg	of	ghrelin	intravenously	to	ensure	approximately	the	same	amount	of	ghrelin	being	measurably	available	in	the	participant’s	organism	during	the	subsequent	cognitive	test	battery	(see	also	supplemental	figure	S1).	Ghrelin	or	placebo	was	administered	consistently	within	test	days,	i.e.	participants	received	either	two	ghrelin	or	two	placebo	injections	on	a	given	test	day.		
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None	of	the	participants	reported	any	adverse	effects	of	ghrelin	administration	such	as	nausea,	vomiting,	headache,	dizziness	or	worse.	As	some	of	these	side	effects	have	been	reported	in	a	previous	systematic	study	on	ghrelin’s	pharmacological	properties	in	humans67,	we	suspect	that	possibly	administration	as	a	semi-bolus	may	be	beneficial.	Although	our	cognitive	test	battery	did	not	include	e.g.	explicit	hunger	ratings	as	a	subjective	indicator	of	ghrelin	efficacy,	participants	were	we	able	to	indicate	their	assumption	about	receiving	ghrelin	with	relatively	high	acuity	on	a	visual	analogue	scale	(74+/-22	vs.	26+/-24	in	the	ghrelin	vs.	placebo	condition,	respectively).		
6.4.3	Cognitive	testing		For	preparation	of	the	learning	task,	participants	trained	on	two	three-dimensional	virtual	tracks	before	every	test	day.	Similar	simulations	of	spatial	navigation	have	been	successfully	used	in	fMRI	studies	of	spatial	and	grid	cell-like	processes	in	the	human	medial	temporal	lobe	before	(Doeller	et	al.,	Nature	2010;	Kunz	et	al.,	Science	2015).	Every	participant	had	to	walk	these	virtual	tracks	(Sauerbraten/Cube	2,	sauerbraten.org)	marked	by	black	boxes	four	times,	once	with	the	help	of	a	test	assistant,	once	on	his	own	and	twice	counting	black	boxes.	These	boxes	were	placed	exactly	where	screenshots	were	taken	of	the	track	and	where	the	words	to	be	learned	the	next	day	would	appear	during	the	learning	sessions.	Screenshots	were	taken	in	approximately	the	same	virtual	distance	and	presented	in	the	order	of	the	track.	The	number	of	boxes	counted	by	the	subject	were	noted	and	compared	to	the	actual	number	placed	on	the	track	in	order	to	control	training	compliance.		 On	the	test	day,	the	spatio-verbal	learning	task	consisted	of	two	encoding	runs	with	50	words	each	(25	food-related,	25	non-food-related),	in	order	to	test	ghrelin	effects	on	both	consolidation	(first	run)	and	encoding	(second	run).	All	words	were	
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common	German	nouns	(note	that	in	figure	1,	nouns	are	shown	in	English	for	better	understanding	only);	encoding	difficulty	was	matched	between	lists	and	tested	in	pilot	trials	in	different	subjects.	The	words	were	presented	on	screenshots	of	the	two	tracks	the	volunteers	had	walked	the	day	before	in	the	order	of	the	black	boxes,	imitating	the	very	same	virtual	walks.	Screenshots	were	presented	in	blocks	of	eight	images	for	2500ms	each,	separated	by	a	jittered	(2500–5000ms)	fixation	cross.	Each	encoding	block	was	started	with	a	brief	instruction	and	contained	4-7	screenshots	with	words	and	1-4	empty	screenshots	in	pseudo-random	order.	For	each	encoding	run,	in	sum,	50	words	were	placed	on	80	screenshots	(i.e.	including	30	word-free	screenshots).	In	between	the	encoding	blocks,	there	was	a	rest	block	(fixation	cross)	of	17.5	seconds,	during	which	participants	had	been	instructed	not	to	rehearse.		Participants´	memory	was	tested	on	the	following	day	in	a	two-steps	retrieval	test.	First,	a	free	recall	session	of	7	min	was	held	in	which	participants	were	asked	to	write	down	on	a	blank	sheet	any	of	the	words	they	still	remembered	from	any	of	the	two	tracks	from	the	previous	day	without	any	cueing.	In	a	second	step,	empty	screenshots	of	the	tracks	used	the	day	before	were	presented	via	the	program	E-Prime.	Each	screenshot	was	presented	for	a	duration	of	3	sec	followed	by	a	30	sec	response	time	(black	screen)	in	which	participants	were	supposed	to	write	down	using	a	computer	keyboard	what	item	they	think	was	placed	on	the	screenshot	of	this	particular	location.	All	of	the	2x80	screenshots	were	presented	during	the	E-Prime	session	regardless	of	whether	a	word	had	been	shown	on	them	or	not.	A	cognitive	test	battery	of	about	60	min	immediately	followed	the	in-fMRI	learning	session	and	subsequent	second	ghrelin	administration.	It	comprised	a	nonverbal	fluid	reasoning	test	(BOMAT,	10	min	version106),	a	working	memory	task	(reverse	digit	span107),	a	creativity	task	(alternative	uses108),	a	perceptual	speed	test	
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(trail	making	task	ZVT109),	and	tests	for	reaction	times	and	psychomotor	vigilance	(PVT110).		
6.4.4	Statistical	analysis		For	free	word	recall,	cued	location-word	association	recall,	and	a	combined	score	including	all	words	correctly	recalled	during	free	or	cued	recall	independent	of	position,	repeated	measures	ANOVAs	were	performed,	each	comprising	the	factors	condition	(ghrelin	or	placebo),	time	(consolidation	vs.	encoding),	and	stimulus	(food	vs.	non-food	items)	for	the	spatial-verbal	learning	task.	For	the	cognitive	test	battery,	a	repeated	measures	ANOVA	with	the	factor	condition	(ghrelin	or	placebo)	was	performed.	All	behavioral	data	was	analyzed	using	IBM	SPSS	Statistics	Version	22	(IBM,	Armonk,	NY),	an	α	of	p<.05	was	considered	significant.	Separate	power	calculations	for	condition	main	effects,	condition	×	time	interactions,	and	condition	×	stimulus	interactions	were	performed	for	each	free	recall,	cued	location-word	association	recall,	and	a	combined	score	of	these	with	G*Power	3111,	assuming	medium	effect	sizes	of	f=.25.	We	further	performed	Bayesian	repeated	measures	ANOVAs	with	default	prior	scales	for	the	free/cued	recall	combined	score	and	the	cognitive	test	battery	using	JASP	Version	0.7.5.6	(jasp-stats.org).		
6.4.5	fMRI	data	acquisition		Whole-brain	 functional	 images	were	acquired	on	a	3T	 (GE	Discovery	MR750)	 scanner	using	a	2D	gradient	echo	planar	image	sequence.	For	both	the	task	and	the	resting	state	scans	we	used	a	repetition	time	(TR)	of	2.5	s,	an	echo	time	(TE)	of	30	ms	and	a	flip	angle	of	90°.	For	the	resting	state	scans	we	acquired	34	interleaved	slices	with	a	field	of	view	
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(FOV)	 of	 24	 cm	 x	 24	 cm,	 a	 matrix	 size	 of	 64	 x	 64,	 resulting	 in	 an	 in-plane	 spatial	resolution	of	3.75	mm,	and	a	slice	thickness	of	3	mm	and	a	slice	gap	of	1	mm.	In	total	192	volumes	were	acquired.	For	the	learning	session	scans	we	acquired	42	interleaved	slices	with	a	FOV	of	24	cm	x	24	cm,	a	matrix	size	of	96	x	96,	resulting	 in	an	 in-plane	spatial	resolution	of	1.875	mm,	and	a	slice	thickness	of	2mm	and	a	slice	gap	of	0.5mm.	In	total	we	acquired	312	volumes.				
6.4.6	fMRI	data	analysis	
	
Preprocessing:	All	fMRI	analyses	were	conducted	using	the	FMRIB	Software	Library	(FSL)	version	6.0112.	For	preprocessing,	the	functional	images	were	corrected	for	effects	of	head	motion	using	MCFLIRT	and	the	brain	was	extracted	using	BET.	Slice	time	correction	was	done	using	Fourier-space	time-series	phase-shifting.	For	spatial	smoothing	we	used	a	Gaussian	kernel	with	full	width	half	maximum	of	6mm.	The	whole	4D	Volume	was	normalized	by	multiplication	by	a	single	factor.	To	remove	temporal	drifts	in	the	data	we	applied	high	pass	filter	with	a	sigma	of	50s.	4	Dummy	volumes	were	acquired	and	discarded.		 Task-based	analyses:	All	the	different	task-based	analysis	used	a	hierarchical	general	linear	model	(GLM)	approach	with	three	levels:	a	run	level,	a	subject	level	and	finally	a	group	level.	On	the	first	level	we	modeled	the	events	during	each	individual	run:	stimulus	onsets	as	well	as	fixation	effects	were	modeled.	The	stimulus	events	were	split	into	later	remembered	and	later	forgotten	items	to	be	contrasted	in	a	subsequent	memory	analysis.	On	the	second	level	the	data	of	the	four	runs	(encoding	1	and	2	in	the	ghrelin	or	placebo	conditions)	were	combined	using	a	fixed	effect	model.	This	combination	was	either	done	by	averaging	all	runs	(task	main	effect),	only	contrasting	the	second	run	placebo	versus	ghrelin	(drug	main	effect)	or	contrasting	the	second	
	 76	
versus	the	first	run	across	the	days	(interaction	run	x	drug).	Then	we	used	a	mixed	effect	model	to	combine	the	results	on	the	subject	level	to	create	the	group	statistics.	Next	to	the	regressors	of	interest	all	first	level	GLMs	contained	nuisance	regressors	for	the	white	matter	and	cerebrospinal	fluid	signal	(1	each,	compartments	were	estimated	using	the	segmentation	tool	of	FSL	fast),	and	24	motion	parameters	(3	parameters	for	rotation,	3	for	translation,	6	derivatives	of	these,	12	squares	of	all	of	these).	All	GLM	contrasts	were	corrected	for	multiple	comparisons	using	clusters	determined	by	Z>2.3	and	a	(corrected)	cluster	significance	threshold	of	p	<	0.05.	Of	note,	while	it	has	recently	been	stressed	that	some	cluster	correction	methods	lead	to	inflated	false	positive	rates,	FSL	FLAME	as	used	here	was	reported	to	be	largely	exempt	from	these	problems	(Eklund	et	al.,	2015).		For	analyzing	the	design	in	a	block	fashion,	we	modeled	the	onset	and	duration	of	the	blocks	and	contrasted	encoding	blocks	with	baseline	fixation	blocks.	To	investigate	whether	ghrelin	modulates	the	BOLD	response	associated	with	the	viewing	of	food	vs.	non-food	words	we	used	regressors	for	the	onsets	of	food	and	no-food	items	and	contrasted	them	within	run	and	across	runs.	To	assess	the	task-related	brain	activity	associated	to	successful	memory	formation	we	performed	a	subsequent	memory	analysis	using	the	later	remembered	items	(either	in	the	free	or	the	cued	recall)	and	contrasted	them	with	the	later	forgotten	items,	independent	of	the	type	of	item	(food	or	non-food).		
	
6.4.7	Resting	state	preprocessing		For	the	resting	state	data	we	applied	the	same	preprocessing	as	for	the	task	scans	except	that	we	removed	two	additional	volumes	at	the	start.	For	the	ROI-based	connectivity	analysis	we	used	ICA-AROMA113,	an	ICA	based	denoising	method	that	filters	
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out	noise	components	from	the	data,	also	we	regressed	the	global	signal	out	as	it	would	confound	ROI	to	ROI	correlation	estimates.	For	the	dual	regression	approach	ICA-AROMA	is	not	necessary	as	the	noise	components	end	up	in	separate	ICA	components.		
Dual	 Regression	 analysis:	 To	 investigate	 ghrelin-induced	 changes	 in	 resting	 state	networks	we	used	dual	regression114.	Since	we	were	most	 interested	in	changes	of	the	default	mode	network	and	the	salience	network,	we	used	the	20	dimensional	ICA	results	of	BrainMap115,116	as	components	to	regress	against.	These	spatial	maps	were	then	used	to	 generate	 subject	 specific	maps	 and	 time	 series	with	 dual	 regression117.	 The	 spatial	maps	were	 then	 compared	 between	 the	 conditions	 using	 the	 randomize	 permutation	test	implemented	in	FSL.		As	a	control	analysis	we	repeated	the	dual	regression,	but	this	time	instead	of	using	the	 established	 networks	 of	 BrainMap	 we	 used	 Melodic	 to	 estimate	 independent	components	on	the	resting	state	data	itself.	To	have	an	unbiased	estimate	we	used	FSL	Melodic	to	estimate	the	ICs	during	post-encoding	rest	in	the	placebo	condition	and	then	regressed	 those	 components	 against	 post-encoding	 rest	 in	 the	 drug	 and	 the	 placebo	condition.	 The	 number	 of	 dimensions	 of	 the	 ICA	 was	 estimated	 using	 the	 Laplace	approximation	to	the	Bayesian	evidence	of	the	model	order.	
	
6.4.8	ROI	based	analysis		For	analyzing	whether	ghrelin	induced	changes	in	functional	connectivity	not	on	a	network	level	but	on	a	smaller	scale,	we	conducted	an	ROI	based	resting	state	analysis.	The	ROIs	were	based	on	previous	studies46,68	and	included	the	amygdala,	hippocampus,	caudate	nucleus,	nucleus	accumbens,	insula	and	the	orbitofrontal	cortex.	We	created	the	ROIs	from	the	Harvard	Oxford	Cortical	and	subcortical	atlas	included	in	FSL.	For	each	region	we	extracted	the	time	series	for	each	voxel.	Between	regions	correlations	were	
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calculated	by	correlating	the	mean	time	series	per	region.	The	correlation	of	each	region	with	the	rest	of	the	brain	was	calculated	by	correlating	the	mean	time	series	of	the	ROI	with	the	mean	time	series	of	the	rest	of	the	brain.	To	test	differences	for	significance	we	used	a	permutation	test.				
	
	
Figure	2:	Ghrelin	administration	did	not	lead	to	improved	memory	encoding	or	consolidation	for	any	of	the	
outcome	measures.	Combined	score	represents	items	that	were	correctly	recalled	in	free	recall	of	words	or	
cued	recall	of	location-word	associations.	Bars	indicate	SEM.	
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Figure	3:	Comparing	both	resting	state	scans	(one	before,	one	after	ghrelin	application),	we	found	decreased	
functional	connectivity	of	the	bilateral	caudate	nucleus	with	the	bilateral	insula	and	right	orbitofrontal	
cortex,	and	of	the	right	caudate	nucleus	with	the	right	amygdala	in	the	ghrelin	condition.	Significant	effects	
on	an	FDR-corrected	p<.05	level	are	indicated	by	an	asterix.				
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Figure	4:	Performance	in	none	of	the	tests	used	in	our	cognitive	test	battery	was	influenced	by	ghrelin	
administration.	Results	in	a	working	memory	task	(reverse	digit	span),	a	fluid	reasoning	test	(BOMAT	
matrices),	a	creativity	task	(alternative	uses),	a	mental	speed	test	(trail	making),	a	reaction	time	task	
(psychomotor	vigilance	task,	PVT:	mean	reaction	times	of	the	fastest	10	reactions	in	ms)	and	an	attention	
task	(PVT:	number	of	misses	defined	as	reaction	time	over	355ms)	were	not	different	between	conditions	(all	
F<2.13,	p>0.16).	Bars	indicate	SEM.		
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6.5	Results		In	contrast	 to	our	hypotheses	and	a	body	of	animal	research,	we	did	not	 find	any	positive	effects	of	ghrelin	administration	on	a	spatial-verbal	learning	task	(figure	2).	As	we	 injected	 ghrelin/placebo	 between	 two	 subsequent	 learning	 runs,	 we	 aimed	 to	differentiate	 between	 potential	 ghrelin	 effects	 on	 pure	 consolidation	 processes	 (first	run,	 before	 ghrelin	 application)	 and	 encoding	 processes	 (second	 run,	 after	 ghrelin	application).	 Given	 that	 previous	 findings	 show	 better	memory	 performance	 for	 food	versus	nonfood	 items	 in	physiological	 states	of	hunger118	 and	after	 ghrelin46,	we	used	food	 and	 non-food	 items	 as	 stimuli.	 In	 a	 repeated	 measures	 ANOVA	 comprising	 the	factors	 condition	 (ghrelin	 vs.	 placebo),	 time	 (consolidation	 vs.	 encoding)	 and	 stimulus	(food	 vs.	 non-food),	we	 observed	 no	 significant	main	 effect	 of	 condition	 on	 free	word	recall	 (F1,20=.356,	 p=.558,	 η2=.017),	 cued	 location-word	 association	 recall	 (F1,20=.014,	p=0.906,	η2=.001)	or	a	combined	score	comprising	all	words	remembered	in	both	free	and	 cued	 recall	 (F1,20=.271,	 p=.608,	 η2=.013).	 We	 further	 observed	 no	 significant	
condition	 ×	 time	 interaction,	 condition	 ×	 stimulus	 interaction,	 or	 condition	 ×	 time	 ×	
stimulus	 interaction	 for	any	of	 the	outcome	measures	 (all	F<1.08,	p>.311,	η2<.051;	see	figure	 2	 and	 supplemental	 table	 T1).	 Given	 our	 sample	 size	 and	 within-subject	correlations	 of	 test	 scores,	 medium-sized	 main	 effects	 of	 ghrelin	 and	 medium-sized	
condition	×	stimulus	 interactions	would	have	been	detected	with	>95%	probability	 for	each	free	recall,	cued	recall	or	a	combined	score	of	these.	Medium-sized	condition	×	time	interactions	would	have	been	detected	with	>90%	probability	 for	 free	recall,	and	with	>95%	 probability	 for	 cued	 recall	 or	 the	 combined	 score.	 Bayesian	 analyses	 of	 the	combined	score	were	 in	 favor	of	 the	Null	model	(condition	BF10=0.25;	condition	×	time	interaction	 BF10=0.33).	 Since	 memory	 was	 nominally	 even	 worse	 under	 ghrelin	 as	
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compared	to	placebo,	positive	effects	of	ghrelin	on	the	performed	memory	tasks	can	be	excluded	with	considerable	confidence.	To	test	the	effects	of	ghrelin	on	a	neurobiological	level,	we	first	analyzed	the	interaction	of	condition	(ghrelin	vs.	placebo)	and	time	(consolidation	vs.	encoding	run)	on	task-related	fMRI	BOLD	response	for	the	contrast	between	encoding	vs.	rest	blocks.	We	found	the	right	occipital	cortex,	right	lingual	gyrus	and	right	fusiform	gyrus	to	be	more	activated	in	the	ghrelin	as	compared	to	the	placebo	condition	(see	supplemental	figure	S2/supplemental	table	T2),	however,	effects	in	neither	of	these	regions	were	related	to	memory	performance	(all	p>.2).	To	further	test	whether	ghrelin	affected	the	task-related	fMRI	BOLD	response	associated	with	successful	memory	formation,	we	conducted	a	subsequent	memory	analysis	and	then	tested	whether	the	activation	was	modulated	by	ghrelin.	Contrasting	all	correctly	remembered	items	with	the	forgotten	ones	per	subject	across	all	sessions	revealed	activation	in	regions	known	to	be	related	with	subsequent	memory	for	words	and	verbal	associations119	such	as	the	left	intraparietal	sulcus,	bilateral	fusiform	gyrus,	left	parahippocampal	gyrus,	and	left	superior	frontal	gyrus,	and	deactivations	in	the	right	frontal	pole	and	right	lateral	occipital	cortex	(see	supplemental	figure	S3/supplemental	table	T3),	which	is	congruent	with	our	design	employing	words	presented	in	front	of	scenes	of	a	virtual	route.	In	a	next	step,	we	tested	if	ghrelin	modulates	this	subsequent	memory	effect	by	contrasting	ghrelin	and	placebo	conditions.	We	found	increased	activation	of	the	left	intraparietal	sulcus,	bilateral	occipital	cortex	and	precuneus	and	decreased	activation	in	the	left	frontal	pole	under	ghrelin	(figure	S3/table	T3).	Again,	however,	these	differences	between	ghrelin	and	placebo	conditions	in	the	subsequent	memory	effect	did	not	correlate	with	memory	performance	(all	p>.4).	In	an	additional	analysis	of	the	fMRI	BOLD	response	associated	with	the	viewing	of	food	stimuli,	we	found	altered	encoding-
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related	brain	processing	for	food	words	as	compared	to	non-food	words	in	the	precuneus,	occipital	cortex	and	left	superior	frontal	gyrus	(see	supplemental	figure	S4).	However,	we	did	not	find	any	enhancing	or	modulating	effect	of	ghrelin	on	the	behavioral	or	neurobiological	effects	of	stimulus	type,	i.e.	food	vs.	non-food	items.		To	 test	 whether	 ghrelin	 modulated	 brain	 activation	 during	 rest,	 we	 first	performed	an	 independent	component	analysis	(ICA)	with	subsequent	dual	regression	on	the	fMRI	resting	state	data	in	order	to	search	for	ghrelin-induced	differences	in	large-scale	 functional	 brain	 networks.	 Setting	 the	 focus	 on	 memory-	 and	 appetite-related	changes,	 we	 restricted	 our	 analysis	 to	 the	 default	 mode	 network	 and	 the	 salience	network.	A	 comparison	of	 functional	 connectivity	within	 these	networks	did	not	 yield	any	significant	differences	between	conditions.		In	addition	to	the	ICA	dual	regression	approach,	we	also	performed	a	connectivity	analysis	of	the	fMRI	resting	state	data	between	the	following	regions	of	interest	(ROI)	of	each	 hemisphere	 based	 on	 previous	 literature46,68:	 hippocampus,	 amygdala,	orbitofrontal	cortex	(OFC),	insula,	caudate	nucleus,	and	nucleus	accumbens.	In	the	post-	as	 compared	 to	 pre-encoding	 resting	 state,	 we	 found	 a	 reduction	 of	 functional	connectivity	 of	 the	 bilateral	 caudate	 nucleus	 with	 the	 right	 orbitofrontal	 cortex	 and	bilateral	 insula,	 and	between	 the	 right	 caudate	 nucleus	 and	 the	 right	 amygdala	 under	ghrelin	compared	to	placebo	(all	pFDR<.05;	see	figure	3).	We	 did	 not	 detect	 any	 influence	 of	 ghrelin	 on	 other	 cognitive	 domains.	Performances	 in	 a	 working	 memory	 task	 (reverse	 digit	 span),	 a	 fluid	 reasoning	 test	(BOMAT	 matrices),	 a	 creativity	 task	 (alternative	 uses),	 a	 mental	 speed	 test	 (trail	making),	and	a	reaction	time	and	attention	task	(psychomotor	vigilance)	did	not	differ	significantly	 under	 the	 influence	 of	 ghrelin	 vs.	 placebo	 (all	 p>0.160;	 figure	 4).	 All	
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Bayesian	 analyses	 of	 the	 cognitive	 test	 battery	were	 in	 favor	 of	 the	 Null	model	 (BF10	between	0.3	and	0.8).	Throughout	both	test	days,	blood	samples	were	first	taken	hourly,	then	every	15	minutes	(figure	1).	In	the	ghrelin	condition,	serum	ghrelin	levels	both	during	the	encoding	block	and	during	the	cognitive	test	battery	(see	supplemental	figure	S1)	were	markedly	higher	than	baseline,	demonstrating	that	participants	performed	all	cognitive	tasks	under	strong	ghrelin	influence	in	the	ghrelin	condition.	
	
6.6	Discussion		Besides	its	role	in	metabolic	processes,	accumulating	evidence	from	animal	models	points	to	an	enhancing	role	of	ghrelin	on	fear	learning,	object	recognition	and	spatial	memory,	in	particular	when	given	before	the	encoding	phase	of	memory	formation1.	On	this	background,	the	central	ghrelin	receptor	has	been	proposed	as	a	target	for	cognitive	enhancement	interventions	also	in	humans	12.	In	contrast	to	animal	research,	however,	evidence	for	a	role	of	ghrelin	in	human	memory	is	sparse.	Memory	for	food-	compared	to	non-food-related	pictures	was	enhanced	after	administration	of	ghrelin	in	an	item	recognition	memory	paradigm	46,	whereas	nocturnal	ghrelin	administration	had	no	positive	effect	on	sleep-related	consolidation	of	a	motor	sequence	learning	task102.	Effects	of	ghrelin	on	more	complex	cognitive	processes	including	encoding	or	consolidation	of	hippocampus-dependent	memories	of	spatial	or	verbal	information	have	not	been	studied	yet.		Many	of	the	cognitive	enhancing	effects	of	ghrelin	in	rodents	were	observed	in	hippocampus-dependent	spatial	learning	tasks	such	as	the	water	maze17	or	the	plus	maze7.	Due	to	its	dual	role	in	appetite	and	memory	regulation,	ghrelin	has	been	
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suggested	to	enhance	spatial	memory	for	food-associated	locations,	possibly	supporting	evolutionary	functions	related	to	foraging98,99.	Our	spatial	learning	task	was	designed	to	associate	appetitive	and	non-appetitive	verbal	material	with	a	background	of	a	naturalistic	environment	based	on	a	three-dimensional	navigational	computer	game,	thereby	testing	this	foraging	function	hypothesis.	In	contrast	to	both	animal	research	and	our	hypothesis,	we	did	not	observe	any	enhancing	effects	of	ghrelin	administration	on	either	the	encoding	or	consolidation	phase	of	a	spatial-verbal	association	task.	This	was	true	for	both	food	and	non-food	related	items,	and	both	for	free	and	spatially	cued	recall.	As	all	learned	stimuli	had	to	be	recalled	one	day	after	encoding,	these	effects	are	independent	from	potentially	modulating	effects	of	ghrelin	on	retrieval.	On	the	neurobiological	level,	ghrelin	increased	activity	in	the	right	occipital	cortex,	right	lingual	gyrus	and	right	fusiform	gyrus	during	encoding	(see	supplemental	figure	S2/supplemental	table	T2),	however	this	effect	was	unrelated	to	memory	performance.	Ghrelin	also	modulated	the	subsequent	memory	effect	in	the	left	intraparietal	sulcus,	bilateral	occipital	cortex,	precuneus,	and	left	frontal	pole.	This	suggests	that	successful	memory	formation	was	achieved	differently	under	ghrelin	as	compared	to	placebo,	however	without	any	effect	on	overt	behavioral	memory	performance.	During	post-encoding	rest,	ghrelin	administration	led	to	decreased	functional	connectivity	of	the	caudate	nucleus	with	the	amygdala,	insula	and	orbitofrontal	cortex	(see	figure	3).	Generally,	ghrelin’s	interaction	with	dopaminergic	brain	circuits	is	well	established,	and	a	negative	association	of	the	connectivity	of	these	brain	regions	with	ghrelin	levels	has	been	demonstrated	for	task-related	fMRI	data	before:	Obese	individuals,	who	are	known	to	exhibit	decreased	ghrelin	levels120,	show	increased	connectivity	of	the	caudate	nucleus	with	the	amygdala,	insula,	and	prefrontal	regions	
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during	presentation	of	appetizing	pictures121.	However,	due	to	the	lack	of	behavioral	ghrelin	effects	on	encoding	or	consolidation	in	our	study,	these	functional	connectivity	changes	are	unlikely	to	be	related	to	memory	processes.	Previous	studies	found	ghrelin	effects	on	pleasantness	ratings	of	food	items	that	mimicked	fasting68.	In	addition,	viewing	food	items	versus	control	increased	ghrelin	release122	and	activated	reward	and	memory	regions	such	as	orbitofrontal	cortex,	nucleus	accumbens,	amygdala,	insula,	hippocampus	and	the	caudate	nucleus68-46.	Enhancing	effects	of	ghrelin	on	recognition	of	food	pictures46	might	therefore	be	mediated	by	enhanced	reward	processing	related	to	food	stimuli123–125.	In	our	study,	we	found	better	free	recall	performance	on	the	behavioral	level	and	altered	encoding-related	brain	processing	for	food	words	as	compared	to	non-food	words	on	the	neurobiological	level	(see	supplemental	table	T1	and	figure	S4).	However,	we	did	not	find	any	enhancing	or	modulating	effect	of	ghrelin	on	the	behavioral	or	neurobiological	effects	of	stimulus	type,	possibly	due	its	abstraction	level	or	salience:	food	names	in	contrast	to	pictures	of	food.	Instead	of	profiting	from	the	intrinsically	rewarding	effects	of	appetizing	stimuli,	participants	might	have	utilized	the	food	category	as	a	cue	that	helped	to	prime	food	words,	thus	leading	to	better	free	recall	in	contrast	to	non-food	words	that	did	not	form	a	single	congruent	category.	This	interpretation	is	supported	by	the	fact	that	no	significant	difference	between	food	and	non-food	stimuli	was	found	for	cued	recall.	Ghrelin’s	role	in	memory	processes	might	thus	be	restricted	to	simple	tasks	with	a	clear	appetitive	component	that	activates	the	reward	system.	In	contrast,	it	does	not	increase	memory	performance	for	more	abstract	or	non-appetitive	information.	A	general	memory	enhancing	effect	of	ghrelin	on	human	memory	would	also	be	inconsistent	with	earlier	findings	that	only	recognition	of	food	pictures	but	not	scenes	
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profited	from	ghrelin	administration46.	In	animal	studies,	memory	tasks	generally	involve	appetitive	stimuli	or	other	highly	salient	components	such	as	fear	in	order	to	motivate	the	animals	to	perform	the	task,	which	might	lead	to	performance	enhancing	effects	in	a	broader	range	of	memory	tasks	in	animal	models.		Baseline	ghrelin	levels	after	an	overnight	fast	as	well	as	ghrelin	levels	immediately	before	the	administration	of	the	first	dose	of	ghrelin	varied	considerably,	despite	matching	of	our	study	participants	regarding	age/weight	and	thorough	standardization	of	all	test	meals,	possibly	due	to	factors	we	did	not	standardize	for	in	our	study	such	as	our	participants’	exact	body	composition126,127.	However,	hyperghrelinemia	achieved	after	intravenous	administration	of	ghrelin	in	our	study	reached	considerably	beyond	the	range	of	endogenous	ghrelin	levels	(supplemental	figure	S1),	thereby	clearly	overcompensating	inter-individual	differences	in	anthropometric	and	metabolic	parameters.	Cognitively	modulating	effects	of	ghrelin	reported	in	other	studies	were	achieved	in	different	metabolic	states,	across	sexes	and	different	age	groups	on	the	basis	on	similarly	supraphysiological	levels	of	ghrelin46,68.	Nonetheless,	future	studies	need	to	address	the	question	of	susceptibility	to	exogenous	ghrelin	administration,	e.g.	by	defining	relevant	metabolic	predictors,	in	order	to	discern	the	subtle	effects	of	ghrelin	on	central	nervous	processes	which	have	been	shown	to	depend	on	metabolic	state	in	rat	models128–130.	As	food	availability	seems	to	play	an	important	role	when	measuring	cognitive	effects	of	the	peptide131,132,	we	strictly	standardized	food	intake	during	test	days.	Further,	order	effects	can	be	a	concern	in	within-subject	crossover	designs,	since	improvements	in	cognitive	tasks	from	first	to	second	session	might	occur	and	interact	with	the	drug.	Including	the	order	of	placebo	vs.	ghrelin	injections	as	a	between	subject	factor	into	the	repeated	measures	ANOVA,	
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however,	we	did	not	find	any	order	×	drug	condition	interaction	effects	on	encoding	or	consolidation	as	assessed	by	either	free	or	cued	recall	(all	F<.2,	p>.6).	It	is	important	to	note	that	recall	was	tested	one	day	after	memory	acquisition.	While	early	studies	on	ghrelin’s	role	in	memory	formation	and	cognition	almost	exclusively	looked	at	short-term	processes	(Carlini	et	al.,	2002;	Diano	et	al.,	2006),	recent	evidence	suggests	that	robust	findings	that	are	also	independent	from	arousal	effects	by	acute	administration	are	found	in	long-term	treatment	studies	(Dhurandhar	et	al.,	2013;	Kunath	et	al.,	2015)	and	likely	depend	on	neurogenic	effects	(Cahill	et	al.,	2014;	Kent	et	al.,	2015;	Hornsby	et	al.,	2016).	A	further	crucial	aspect	in	the	interpretation	of	the	lack	of	behavioral	effects	is	the	possibility	that	i.v.	ghrelin	did	not	reach	those	brain	regions	relevant	for	learning	and	memory.	In	animal	models,	divergent	findings	suggest	that	there	may	be	differences	between	species	concerning	the	amount	of	ghrelin	crossing	the	blood-brain	barrier	and	the	relevant	binding	sites7,133,134.	We	can	present	only	indirect	indicators	as	to	what	extent	active	ghrelin	actually	crossed	the	blood-brain	barrier	and	became	available	to	learning-related	brain	regions.	Whereas	we	observed	amygdala	connectivity	to	be	modulated	by	ghrelin	during	post-encoding	resting	state,	we	did	not	find	hippocampal	activity	to	be	affected	by	ghrelin	during	either	task	or	rest.	Future	studies	in	humans	involving	technologies	such	as	MR-spectroscopy,	PET-MRI	or	the	measurement	of	cerebrospinal	fluid	levels	may	draw	a	clearer	picture	of	how	and	where	exactly	centrally	available	ghrelin	modulates	brain	metabolism.	Given	ghrelin’s	considerable	interactions	with	glucose	homeostasis54,135,136,	such	studies	should	also	consider	the	possibility	that	indirect	effects	mediated	by	systemically	higher	or	lower	glucose	levels	made	available	for	brain	metabolism	may	be	more	important	than	the	actual	direct	binding	of	ghrelin	to	the	GHS-R1a	itself.		
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The	aim	of	this	study	was	to	draw	a	more	comprehensive	picture	of	ghrelin’s	short-term	effects	on	human	memory	and	general	cognitive	performance.	As	we	observed	no	improvement	in	any	cognitive	domain	tested	in	our	trial,	we	conclude	that	ghrelin	does	not	generally	act	as	a	short-term	cognitive	enhancer	in	humans.	Differences	in	the	fMRI	subsequent	memory	effect	suggest	that	successful	memory	formation	might	have	been	achieved	differently	under	ghrelin,	however	without	any	effect	on	overt	behavioral	memory	performance.	It	will	have	to	be	tested	if	this	lack	of	behavioral	effect	in	humans	will	also	hold	for	information	with	stronger	appetitive	valence	or	fear/stress	components	and	under	a	long-term	perspective.	We	suggest	that	future	studies	aiming	at	transferring	the	promising	data	on	ghrelin’s	memory	effects	in	rodents	on	human	samples	should	make	a	clear-cut	differentiation	of	ghrelin’s	short-term	actions	as	an	orexigenic	neuropeptide	possibly	modulating	certain	cognitive	functions	such	as	food	preference	and	appetitive	behavior46,122,137,138	and	its	potential	neuroprotective	effects	in	long-term	or	pathological	models16,17,70,	at	the	same	time	thoroughly	taking	into	account	aspects	of	susceptibility	and	dosage.				
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6.7	Supplemental	data			
	 free	word	recall	 cued	association	recall	 combined	score	drug	 F1,20=.356,	p=.558,	η2=.017	 F1,20=.014,	p=.906,	η2=.001	 F1,20=.271,	p=.608,	η2=.013	time	 F1,20=6.415,	p=.020,	η2=.243	 F1,20=3.237,	p=.087,	η2=.139	 F1,20=8.700,	p=.008,	η2=.303	stimulus	 F1,20=8.273,	p=.009,	η2=.293	 F1,20=.816,	p=.377,	η2=.039	 F1,20=3.720,	p=.068,	η2=.157	drug	×	time	 F1,20=.059,	p=.811,	η2=.003	 F1,20=.018,	p.896=,	η2=.001	 F1,20=.023,	p=.882,	η2=.001	drug	×	stimulus	 F1,20=.828,	p=.374,	η2=.040	 F1,20=.028,	p=.868,	η2=.001	 F1,20=.545,	p=.469,	η2=.027	time	×	stimulus	 F1,20=.247,	p=.625,	η2=.012	 F1,20=1.850,	p=.189,	η2=.085	 F1,20=.070,	p=.794,	η2=.003	drug	×	time	×	stimulus	 F1,20=.589,	p=.452,	η2=.029	 F1,20=1.079,	p=.311,	η2=.051	 F1,20=.328,	p=.573,	η2=.016		
Supplemental	Table	T1:	For	the	three	different	outcome	measures	free	word	recall,	cued	location-word	
association	recall,	and	a	combined	score	of	these	two,	repeated	measures	ANOVAs	comprising	the	factors	
drug	(ghrelin	vs.	placebo),	time	(consolidation	vs.	encoding)	and	stimulus	(food	vs.	non-food)	did	not	reveal	
any	significant	main	effect	of	drug	and	no	significant	interaction	of	drug	with	any	of	the	other	factors.	The	
analyses	did	reveal	significant	main	effects	of	time,	probably	due	to	more	interference	in	the	second	as	
compared	to	the	first	encoding	run.	Further,	the	analyses	did	reveal	a	significant	stimulus	effect	for	free	
recall,	suggesting	that	participants	could	utilize	the	food	category	as	a	cue	that	helped	to	recall	food	words.	
Non-food	word	did	not	stem	from	a	single	congruent	category,	hence	no	categorical	cue	could	be	utilized	for	
these.	This	interpretation	is	supported	by	the	fact	that	no	significant	stimulus	effect	was	found	for	cued	
location-word	association	recall.		
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Voxels	 P	 Z	max	 Z-max	X	 Z-max	Y	 Z-max	Z	 Z-COG	X	 Z-COG	Y	 Z-COG	Z	645	 0.000938	 3.49	 32	 -82	 24	 25.8	 -78	 34.1	408	 0.0195	 3.66	 24	 -60	 -10	 24.1	 -70.6	 -6.67		
Supplemental	Table	T2:	Cluster	showing	a	significant	interaction	of	condition	(ghrelin	vs.	placebo)	and	time	
(consolidation	vs.	encoding)	in	the	positive	contrast	between	encoding	vs.	baseline	blocks.	Effects	are	cluster-
corrected	at	p<0.05	with	Z>2.3.	For	each	significant	cluster,	the	number	of	voxels,	the	p-value,	the	maximum	
z-value,	MNI	space	coordinates	of	the	maximum	z-value	voxel,	and	coordinates	of	the	center	of	gravity	(COG)	
are	given.																									
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		Subsequent	memory	effect,	positive	contrast:	Voxels	 P	 Z	max	 Z-max	X	 Z-max	Y	 Z-max	Z	 Z-COG	X	 Z-COG	Y	 Z-COG	Z	1815	 3.57E-10	 3.71	 -40	 -50	 62	 -28.1	 -60.9	 52.7	817	 2.06E-05	 3.48	 -34	 -30	 -20	 -46.9	 -58.6	 -2.7	812	 2.20E-05	 3.95	 10	 10	 66	 -1.61	 11.6	 61.7	671	 0.000141	 3.4	 -28	 -2	 64	 -41.8	 4.76	 43.2	347	 0.0181	 3.48	 50	 -42	 -20	 47.5	 -50.1	 -11.8		Subsequent	memory	effect,	negative	contrast:	Voxels	 P	 Z	max	 Z-max	X	 Z-max	Y	 Z-max	Z	 Z-COG	X	 Z-COG	Y	 Z-COG	Z	803	 2.47E-05	 3.47	 54	 -60	 42	 50.6	 -59.6	 42.8	422	 0.00534	 3.82	 46	 46	 -8	 44.3	 49.5	 -4.82	346	 0.0184	 3.35	 14	 70	 18	 16.6	 62.5	 25.4	337	 0.0215	 3.62	 4	 -48	 22	 5.51	 -47	 26.9		Ghrelin	modulation	of	the	subsequent	memory	effect,	positive	contrast:	Voxels	 P	 Z	max	 Z-max	X	 Z-max	Y	 Z-max	Z	 Z-COG	X	 Z-COG	Y	 Z-COG	Z	
1824	 4.65E-10	 3.75	 20	 -88	 16	 15.9	 -72.1	 22.7	
611	 0.000381	 3.75	 -36	 -48	 70	 -37.7	 -49.6	 63.2	
442	 0.00446	 3.37	 -34	 -84	 16	 -31.1	 -80.3	 19.2		Ghrelin	modulation	of	the	subsequent	memory	effect,	negative	contrast:	Voxels	 P	 Z	max	 Z-max	X	 Z-max	Y	 Z-max	Z	 Z-COG	X	 Z-COG	Y	 Z-COG	Z	
406	 0.00781	 3.47	 -20	 58	 8	 -15	 64	 5.27	
	
Supplemental	Table	T3:	Cluster	showing	a	significant	subsequent	memory	effect	(words	remembered	vs.	
words	forgotten	after	24h,	combined	score	comprising	all	words	recalled	in	free	or	cued	recall),	and	a	
significant	modulation	by	ghrelin	of	the	significant	subsequent	memory	effect.	Effects	are	cluster-corrected	at	
p<0.05	with	Z>2.3.	For	each	significant	cluster,	the	number	of	voxels,	the	p-value,	the	maximum	z-value,	MNI	
space	coordinates	of	the	maximum	z-value	voxel,	and	coordinates	of	the	center	of	gravity	(COG)	are	given.		 	
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Supplemental	Figure	S1:	a)	Group	average.	Serum	ghrelin	levels	were	significantly	higher	(p<0.0001	each)	
both	after	the	first	and	after	the	second	injection	than	at	baseline	(„before	inj1“,	averaged	values	of	samples	
taken	before	the	first	injection).	Bars	indicate	SEM.	b)	Serum	acyl	ghrelin	levels	rose	sharply	after	the	first	
injection,	then	took	a	short	dip	due	to	ghrelin’s	short	half-life	time	and	rose	again	after	the	second	injection	
before	vanishing	towards	the	end	of	each	test	day.	Both	during	the	second	learning	phase	inside	the	MRI	
scanner	and	during	the	cognitive	test	battery,	supraphysiological	serum	acyl	ghrelin	levels	could	be	
measured	in	all	participants.			
	
Supplemental	Figure	S2:	Interaction	of	condition	(ghrelin	vs.	placebo)	and	time	(consolidation	vs.	encoding)	
in	the	contrast	between	encoding	vs.	baseline	blocks.	Effects	are	cluster-corrected	at	p<0.05	with	Z>2.3.	See	
supplemental	table	T2	and	text	for	details.	
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Supplemental	Figure	S3,	top:	Subsequent	memory	analysis	of	words	remembered	vs.	words	forgotten	after	
24h	(combined	score	comprising	all	words	recalled	in	free	or	cued	recall).	Bottom:	Subsequent	memory	effect	
as	modulated	by	ghrelin.	Effects	are	cluster-corrected	at	p<0.05	with	Z>2.3.	See	supplemental	table	T3	and	
text	for	details.		 	
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Supplemental	Figure	S4:	Brain	activation	related	to	the	presentation	of	food	vs.	non-food	words	(main	
effect).	Effects	are	cluster-corrected	at	p<0.05	with	Z>2.3.	See	text	for	details.						
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